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Abstract 
 
Systemic sclerosis is a chronic, fibrotic disorder associated with high disease-specific mortality 
and morbidity. Cutaneous manifestations include dermal thickening and obliteration of dermal 
adipose tissue. The efficacy of function-blocking Rhamm peptides, NPI-110 and NPI-106, were 
tested in reducing skin fibrosis and promoting adipogenesis in a bleomycin-induced mouse model 
of systemic sclerosis. NPI-110 reduced both visible measures of fibrosis (dermal thickness, 
collagen density, and fibril bundling) and mRNA expression of pro-fibrotic genes (Tgfb1, c-Myc, 
Col1a1, Col3a1). While there was no measurable change in dermal adipose thickness, NPI-110 
treatment upregulated Perilipin mRNA and Adiponectin protein expression and is therefore 
hypothesized to create a pro-adipogenic microenvironment. NPI-106 was less effective in 
reversing dermal fibrosis and did not affect adipogenesis. Transcriptomic analyses suggest a 
mechanism where Rhamm stabilizes β-catenin, activates Erk1 and c-Myc, and causes fibroblast 
activation and suppression of adipocyte differentiation. Rhamm function-blocking peptides 
reverse these effects and present a novel treatment method for cutaneous fibrosis in systemic 
sclerosis.  
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1 Introduction 
 
1.1 Systemic Sclerosis  
Systemic sclerosis (SSc) is a chronic, progressive, disorder characterized by extensive cutaneous 
and visceral fibrosis1,2. The estimated prevalence ranges from 0.07 to 5 per 100 000 depending on 
ethnicity and geographic location, with the highest prevalence in North America3,4 Although a rare 
disease, SSc has the highest mortality of all rheumatologic conditions with a median survival from 
time of diagnosis of 11 years5. The cumulative 5-year survival following diagnosis is 74.9%, and 
10-year survival is only 62.5%1,3 with mortality due to progressive visceral organ fibrosis, 
interstitial lung disease, and pulmonary arterial hypertension6,7.  
 
This high disease-specific mortality rate is also associated with substantial morbidity, as the 
disabling multisystemic effects of SSc pervade across all aspects of daily life. Although not life 
threatening, progressive fibrosis and thickening of the skin, especially of the hands and face, 
present a significant burden for patients. Skin tightness and joint contractures can lead to 
impairments in hand function, mobility, and significant disability. Fibrosis around the mouth 
results in difficulties with mouth opening that interfere with the basic tasks of speaking and eating1. 
Similarly, disfiguring changes in facial appearance causing ‘mask-like facies’ and loss of facial 
expressions are a source of social distress and self-image issues8,9. This is further compounded by 
the psychologic impact due to the progressive and heterogenous disease course with the 
uncertainty of future disease progression10–12.  
 
1.1.1 Classification 
The term scleroderma has recently been replaced with more precise nomenclature to describe the 
four subtypes of systemic sclerosis based on clinical symptoms, autoantibody production, and 
systemic involvement: limited cutaneous systemic sclerosis (LcSSc, previously also CREST 
syndrome), diffuse cutaneous systemic sclerosis (DcSSc), morphea, and systemic sclerosis sine 
scleroderma13. LcSSc describes a disease subset with sclerotic changes of the face and only of the 
skin distal to the elbow and knees, associated with a high risk of interstitial lung disease and 
pulmonary hypertension. In contrast, DcSSc involves skin changes of both the proximal and distal 
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extremities and a predilection towards developing interstitial lung disease, progressive lung 
fibrosis, renal crisis, and significant hand disability with Raynaud’s phenomenon and digital 
ulcers13. Morphea, previously known as localized scleroderma, refers to involvement limited to 
the skin without associated visceral organ fibrosis. Controversy still exists as to whether morphea 
represents an early manifestation of systemic sclerosis or actual distinct subtypes14. Systemic 
sclerosis sine scleroderma manifests with the fibrosis of visceral organs without cutaneous 
fibrosis15.  
 
Currently, there are no curative or disease modifying therapies for systemic sclerosis. Treatment 
is directed towards symptom and complication management and there remains an urgent need for 
the development of targeted anti-fibrotic therapies. This lack of effective treatment options stems 
from the incomplete understanding of the etiology of systemic sclerosis. 
 
1.2 Pathophysiology  
 
1.2.1 Etiology 
Systemic sclerosis is an autoimmune disease emerging from the complex interplay of genetic 
predisposition and environmental factors, with an unknown exact etiology. Geo-epidemiologic 
studies show higher prevalence and mortality rates within African American populations16 as well 
as in certain rural communities found to have specific HLA haplotypes that confer disease 
susceptibility17. However, genetic factors cannot fully explain the development of SSc, as there is 
an extremely low clinical concordance of SSc within monozygotic twins18,19, suggesting the 
presence of secondary acquired genetic or environmental triggers. Occupational exposures (silica 
dust, organic and chlorinated solvents, epoxy resins)1,20, chemotherapy or radiotherapy 
treatment21, and certain infection (cytomegalovirus, parvovirus B19, Ebstein Barr virus, and 
Helicobacter pylori)2 have all been implicated as possible inciting agents. This is further 
complicated by the multitude of systemic sclerosis-like diseases (scleromyxedema, eosinophilic 
fasciitis, porphyria cutanea tarda, diabetic cheiroartropathy)22 and subtypes of systemic sclerosis 
which may be a result of similar but divergent mechanisms.   
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1.2.2 Fibroblasts 
A cardinal feature of SSc is thickening and fibrosis of the skin. Fibrosis occurs from the excessive 
deposition of extracellular matrix (ECM) products such as collagen, fibronectin, and hyaluronan 
by activated fibroblasts23,24. Fibroblasts are the predominant cells in connective tissues that 
regulate ECM synthesis and turnover. During homeostasis, they maintain a balance between 
matrix production and breakdown  through expression of matrix proteins/proteoglycans as well as 
various matrix proteinases and glycosidases25.  
 
A primary event, such as viral toxins, aberrant autoantibody activation, or vascular endothelial 
injury precedes fibrosis and causes the upregulation of pro-inflammatory signals resulting in the 
activation of fibroblasts23,26. Activated fibroblasts are able to differentiate into myofibroblasts, 
which resemble smooth muscle cells in phenotype. Myofibroblasts are positive for the marker 
alpha-smooth muscle actin (αSMA) and actively synthesize, bundle, and contract collagen fibrils. 
These processes are normal parts of wound healing, where myofibroblasts help to contract the 
wound edges and deposit ECM products required for granulation tissue formation. This activity is 
normally attenuated by myofibroblast apoptosis; however, if myofibroblast activity is sustained, 
then tissue fibrosis ensues.  For example in SSc, fibroblasts subvert these intrinsic regulatory 
mechanisms, resulting in unopposed fibroblast activation independent of external stimuli, leading 
to the ongoing pathologic remodelling of the ECM26,27.   
 
1.2.3 Tgfb1 
Tissue fibrosis is driven by transforming growth factor β (Tgfb1), a master regulator involved in 
wound healing, inflammation, and pathologic fibrosis28,29. Tgfb1, a fibrogenic cytokine, is 
uniformly upregulated in fibrotic tissues and induces fibroblasts to differentiate into 
myofibroblasts29. Activated fibroblasts both upregulate the production of Tgfb1, increase their own 
expression of Tgfb1 receptors, and produce factors such as connective tissue growth factor (Ctgf), 
a cofactor that enhances Tgfb1 binding30, to establish a vicious cycle of autocrine stimulation31.  
 
Understanding of the origin of activated fibroblasts and myofibroblasts is evolving.  
Myofibroblasts in SSc have long been thought to arise from resident fibroblasts in the affected 
tissues; however, recent research using new experimental tools for lineage tracing suggest a role 
for ‘cell-fate switching’26,32 with the involvement of numerous other adult cell types. Epithelial 
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cells33,34, endothelial cells35, pericytes36, fibrocytes37, and adipocytes38,39  have been shown to 
trans-differentiate into activated myofibroblast-like cells which are positive for αSMA and can 
produce and bundle collagen. Tgfb1 signaling has been implicated in guiding this cellular plasticity 
since it can induce both epithelial-mesenchymal transition (EMT)  and endothelial-mesenchymal 
transition (EndoMT) in culture35,40. In vivo lineage tracing studies have shown that dermal 
adipocyte progenitors also contribute to the population of activated fibroblasts and 
myofibroblasts39. In culture analyses of human adipocyte-derived progenitor cells confirm that 
Tgfb1 induce myofibroblast-like changes in adipocyte phenotype and transcriptome39. 
Collectively these studies point to a more complex and active role of the dermal adipose tissue in 
the development of cutaneous fibrosis, rather than just mere consequence of fibrotic changes.  
 
1.2.4 Dermal adipose tissue  
In addition to dermal thickening, a consistent but less well-recognized finding is the loss of dermal 
adipose tissue in SSc41. This is seen in both excisional biopsies of patients with SSc and in multiple 
animal models of SSc and cutaneous fibrosis42–44. This loss of dermal adipose tissue is a result of 
both adipocyte apoptosis and cellular reprogramming of adipocytes into myofibroblasts, 
suggesting the primary pathological mechanism of SSc may reside within dermal adipose tissue 
rather than in the dermis39.  
 
Dermal adipose tissue is a layer of unilocular adipocytes found surrounding hair follicles and 
pilosebaceous units45. In rodents, which are loose skinned, the dermal adipose tissue is between 
the reticular dermis and panniculosus carnosus muscle layers. This is an adipocyte depot separate 
from the subcutaneous adipose tissue layer, which is found deeper to the panniculosus carnosus45. 
Human skin does not have a panniculosus carnosus layer and the dermal adipose tissue form cone-
like extensions surrounding the hair follicular unit. The dermal adipose tissue lies superficial to, 
and is histologically and metabolically distinct from, the subcutaneous adipose tissue46 (Figure 1). 
In both human and rodent skin, dermal adipose tissue lies directly below the reticular dermis, and 
this positional information may inform cell-fate decision making. Fibroblasts demonstrate 
‘positional identity’ and their transcriptomic profiles vary according to anatomic location47. 
Aberrant signalling within dermal adipose tissue may cause the adjacent reticular fibroblasts to 
lose their ‘positional memory’ and progress towards fibrosis47.  
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Figure 1. Comparative anatomy of human and mouse skin. Schematic diagram of layers within 
human and mouse skin illustrating differential location of the dermal adipose tissue layer. In 
human skin, the dermal adipose tissue form cones surrounding the hair follicular unit and is directly 
superficial to, but distinct from, the subcutaneous adipose tissue. In mouse skin, the dermal adipose 
tissue is separated from the subcutaneous adipose layer by the panniculosus carnosus, which is 
absent in humans.    
6 
 
1.2.5 Ppary 
The nuclear transcription factor peroxisome proliferator-activated receptor gamma (Ppary) is a 
master regulator of adipogenesis and lipoprotein metabolism. Originally identified in adipocytes, 
Ppary is also expressed in macrophages, endothelial cells, and fibroblasts48,49. Adipocyte 
development occurs in two main steps. Mesenchymal stem cells first become preadipocytes, which 
are cells restricted to an adipocytic fate, and then Ppary directs the terminal differentiation of 
preadipocytes into mature adipocytes50.  
 
Importantly, Ppary not only promotes adipogenesis but also has potent intrinsic anti-fibrotic 
effects23,26. The expression of Ppary is reduced in skin biopsies from SSc patients as well as in 
monocytes of healthy African Americans, who have a much higher susceptibility to developing 
SSc51,52. Ppary expression attenuates Tgfb1-stimulated collagen production and myofibroblast 
differentiation53,54. Furthermore, exogenous ligands of Ppary block Tgfb1-induced epithelial-
mesenchymal transition in lung fibrosis and promote the differentiation of mesenchymal 
progenitor cells into adipocytes instead of fibroblasts55,56. Rosiglitazone, an approved insulin-
sensitizing agent and Ppary agonist, reduces both dermal fibrosis and loss of dermal adipose tissue 
in animal models of SSc42,56. This effect is, however, reduced by Tgfb1 which has also been shown 
to potently inhibit Ppary expression42. The reciprocally inhibitory nature of Tgfb1 and Ppary 
highlight the intricate and complex balance between adipogenesis and fibrosis.  
 
1.2.6 Adiponectin  
The circulating adipokine, adiponectin, is only produced by adipocytes and mediates many of the 
anti-fibrotic effects of Ppary. Patients with DcSSc have lower circulating levels of serum 
adiponectin, which inversely correlates with disease severity57–59. Adiponectin expression is under 
the direct transcriptional control of Ppary60, which induces the production of circulating 
adiponectin by adipocytes. In SSc fibroblasts, adiponectin suppresses collagen and αSMA 
expression and attenuates Tgfb1-induced activation of fibroblasts54,61. This illuminates a key 
feedback mechanism for blocking fibrosis whereby the downstream effector of Ppary, adiponectin, 
exerts inhibition of Tgfb1 signalling.  
 
 
 
7 
 
1.2.7 Wnt/β-catenin  
Another key player in the pathogenesis of SSc is Wingless (Wnt), a member of a large family of 
secreted glycoproteins that regulate cell fate determination and morphogenesis in early 
development. Through its canonical signalling pathway, binding of Wnt ligands stabilize β-
catenin, which translocates to the nucleus and controls transcription of downstream pro-fibrosis 
target genes62,63. One specific Wnt ligand, Wnt10b, is increased in lesional SSc skin and drives 
fibrosis64. Mice over-expressing Wnt10b exhibit increased collagen production and activation of 
fibroblasts64.  
 
The canonical Wnt signalling pathway also inhibits adipogenesis and causes lipoatrophy in 
transgenic mice64–67. Elegant lineage tracing studies have demonstrated that the lower reticular 
dermis shares a common embryologic origin with pre-adipocytes and mature adipocytes68. In early 
development, selective activation of β-catenin in the lower reticular dermis increases fibroblast 
proliferation and decreases adipocyte differentiation69. Based on in vitro studies, β-catenin 
suppresses adipogenesis by inhibiting Ppary-directed terminal differentiation of adipocytes, and 
thus switches the transcriptional programme towards a fibroblastic fate63.  
 
SSc was initially understood to result from dysregulated signalling within the dermis; however, 
recent research has refocused the lens on the interface between the reticular dermis and dermal 
adipose tissue. Tgfb, Ppary, and Wnt/β-catenin demonstrate mutually antagonistic effects and 
multiple layers of control that maintain the tight balance between adipogenesis and fibrosis. The 
disruption in this equilibrium may be the hallmark in the pathogenesis of SSc. 
 
 
1.3 Hyaluronic Acid 
Hyaluronic acid (HA), which is found ubiquitously in the ECM and affects both fibrosis and 
adipocyte differentiation, may be the homeostatic thermostat regulating this equilibrium. HA is a 
large, linear glycosaminoglycan consisting of the repeating disaccharides D-glucuronic acid and 
N-acetyl-D-glucosamine70. Although HA is found in abundance in all tissues, more than 50% of 
total body HA resides in the dermis71. In its native, high-molecular weight form, HA (HMW-HA 
> 500kDa) maintains homeostasis as a hydrophilic viscoelastic structural macromolecule that 
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provides hydration and mechanical integrity to tissues. HMW-HA also acts as a template for the 
organization of extracellular matrix structures72,73. HMW-HA suppresses inflammation and 
fibrosis72,74–76 by spatially protecting cells from immune recognition, and blocking macrophage 
infiltration77,78. Locally, HMW-HA provides an ‘adipogenic niche’ supporting pre-adipocyte 
survival and differentiation, maintaining the ‘stemness’ of mesenchymal progenitors79–81. 
In the event of tissue injury, reactive oxygen/nitrogen species and hyaluronidases are released from 
damaged cells which fragment HMW-HA into pro-inflammatory lower molecular weight 
oligosaccharides (<500kDa)82–84. These fragments stimulate wound repair processes, such as 
inflammation, fibroblast migration, myofibroblast differentiation, and ECM production85–87. The 
persistence of fragmented low molecular weight HA (LMW-HA) leads to unremitting 
inflammation with a pathologic consequence of fibrogenesis and tissue architecture destruction88. 
The accumulation of LMW-HA fragments is demonstrated in liver fibrosis, asthma, inflammatory 
bowel disease, and rheumatoid arthritis amongst many other diseases75,89–91. SSc patients have also 
been found to have higher serum levels of LMW-HA, which is positively correlated with the extent 
of cutaneous involvement and severity of systemic disease92–95. LMW-HA fragments are not only 
pro-fibrotic76,96,97 but anti-adipogenic98,99  and suppress adipocyte differentiation. Collectively this 
strongly suggests a role for LMW-HA in mediating the pathologic effects of dermal thickening 
and dermal adipose atrophy in SSc.   
 
1.3.1 HA Receptors 
HA acts through a variety of receptors, most importantly, CD44 and Rhamm (CD168, receptor for 
hyaluronan-mediated motility, encoded by gene hmmr). CD44 is a constitutively expressed 
integral membrane protein involved in the cellular cytoskeletal dynamics of proliferation and 
migration96,100,101. Conversely, Rhamm is transiently expressed only following tissue injury102 and 
preferentially binds to LMW-HA fragments. Rhamm is found as an extracellular and intracellular 
protein101,103,104. Extracellular Rhamm, which binds to CD44, activates a number of intracellular 
kinases, in particular the mitogen-activated protein (MAP) kinases, Erk1 and 2, (extracellular 
signal-related kinase 1, 2), which are involved in fibroblast motility and mesenchymal cell 
differentiation101,105. Erk1 maintains a clonally expanded pre-adipocyte population but prevents 
their progression towards terminal adipocyte differentiation by inhibiting Pparγ105,106. Rhamm-
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deficient mice exhibit increased adiposity attributed to relief of Ppary suppression by loss of Erk1 
activity, which allows the differentiation of preadipocytes into mature adipocytes107. Intracellular 
Rhamm acts as an adaptor molecule linking signalling complexes to the cytoskeleton and 
complexes with Erk1,2 to direct its subcellular targeting101,108. Cell surface Rhamm associated with 
CD44, controls cellular lamella, focal adhesion turnover, and cellular motility through Erk1,2 
activity100,108. Rhamm expression is regulated by Tgfb1 and is a downstream effector of this 
cytokine in its induction of fibroblast motility and maintenance of myofibroblast 
differentiation101,109. Tgfb1 also promotes production of LMW-HA, which further contributes to 
myofibroblast differentiation110,111.  
Thus, depending on its molecular weight, HA can function either as a homeostatic balance or as 
the first distress signal that initiates inflammation. HA molds the cellular microenvironment by 
preferentially sequestering signalling molecules while blocking others. When fragmented, its 
signalling through Rhamm promotes the pro-fibrotic (Tgfb1) and anti-adipogenic (Erk1/2) 
environment seen in many pathological fibrotic diseases.  
 
1.4 Developing Targeted Therapies  
 
With no approved disease modifying treatments, the mainstay of systemic and DsSSc management 
is oral immunosuppressant agents and symptomatic management of cutaneous fibrosis. Many 
treatments have been tried for cutaneous fibrosis, including topical immunosuppressants, 
vasodilator drugs, phototherapy, and physiotherapy which have limited benefit and efficacy2,3.   
 
The development of effective targeted therapeutic interventions remains a challenge. Tgfb1, one 
of the main drivers and regulators of fibrosis, is an obvious target; however, it has pleiotropic and 
often opposing effects on inflammation, which have lead to adverse effects. While Tgfb1 
expression in macrophages results in pro-fibrotic downstream effects, its expression in CD4+ 
regulatory cells is anti-inflammatory112. Tgfb1 disruption in mice is lethal at 3 weeks due to diffuse 
multi-focal inflammation113. Ppary agonists, which are clinically approved as insulin-sensitization 
agents in diabetes, have shown promising results in reversing fibrosis in animal models. However, 
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their substantial side effects, including weight gain, peripheral edema and cardiac complications, 
preclude their use as a sustainable treatment option114,115.  
 
Rhamm is an attractive therapeutic target for its specific expression within injured and fibrotic 
tissues, which also uniquely accumulate LMW-HA. The hyaluronan binding region of Rhamm is 
different from other HA receptors in that it demonstrates preferential binding to smaller 
inflammatory HA fragments116,117 and has nM rather than µM affinity for these fragments. Since 
LMW-HA fragments represent a small percentage of HA even in injured tissues, these two HA 
binding properties of Rhamm provide an opportunity to efficiently and selectively sequester 
LMW-HA as a method for preventing pro-inflammatory and pro-fibrotic signaling.  In addition, 
the restricted expression of Rhamm and LMW-HA predict limited off-target side effects and a 
good safety profile.  
 
1.4.1 Function-blocking RHAMM peptides  
Rhamm function-blocking peptides have recently been developed based on the HA:Rhamm 
binding sequence. These peptides function through two mechanisms: 1) binding to and 
sequestering HA fragments away from interacting with downstream receptors 2) binding directly 
to Rhamm and sterically preventing its association with HA fragments.  
The HA receptors CD44, Lyve1 and Hare bind to the link-protein on HA through a conserved 100 
amino acid region that forms a long shallow shelf which larger HA polymers fit into118. In contrast, 
HA:Rhamm binding sequences forms two helices connected by a linker sequence that wrap around 
short HA polymers. HA:CD44/Lyve1/Stab-2/Hare interactions thus require conformational fit 
while HA:Rhamm interactions rely upon ionic bridges and specific basic amino acids interactions. 
The HA:Rhamm binding domains contain the BX7B motif where B is any basic amino acid and X 
represents any non-acidic residues119,120. The first rationally designed HA-binding peptide, NPI-
106, was based on this Rhamm motif. NPI-106 has the amino acid sequence RGGGRGRRR (R, 
arginine; G, glycine residues) and other than a BX7B motif, has no other sequence homology to 
Rhamm117. The basic residues spaced 7 amino acids apart allow for ionic interactions between 
NPI-106 and the carboxylate ions on the HA molecule119, effectively sequestering the HA 
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fragment away from activating its receptors. In a mouse model of bleomycin-induced lung fibrosis, 
NPI-106 strongly reduces macrophage chemotaxis, Col1a1 mRNA expression, and 
hydroxyproline content in the lung97,121.  
Rhamm sequence-mimetic peptides have also been identified that bind to Rhamm via a homo-
dimerization sequence in the linker region between the two HA binding helices and disrupt 
interaction with HA. The peptide NPI-102 (644KLKDENSQLKSEVSK) sterically blocks a leucine 
zipper necessary for Rhamm signalling107,117. NPI-110 is based on the same peptide sequence as 
NPI-102 but contains acetylated ends which renders it insensitive to cleavage by proteases and 
increases its serum half-life to over 24 hours. NPI-110 was identified by screening for peptides 
that promoted the survival and adipogenic differentiation of bone marrow mesenchymal stem cells 
and the differentiation of human and mouse pre-adipocytes into mature adipocytes107. Injections 
of NPI-110 promotes subcutaneous adipogenesis in the dorsal skin and mammary fat pads of rats 
and increases the expression of both Ppary and adiponectin.  In a model of radiation-induced 
mammary fat pad fibrosis, NPI-110 attenuates radiation-induced fibrosis and increases the 
expression of adiponectin122.  Collectively, this supports the hypothesis that blocking Rhamm 
signaling, and thus Erk1 activity, will relieve the inhibitory effects of this MAP kinase upon Ppary, 
allowing terminal differentiation of adipocytes.  
 
 
1.5 Animal Models  
 
A well-established mouse model of SSc is daily subcutaneously injections of bleomycin (BLM)123, 
an anti-tumour antibiotic isolated from Streptomyces verticillus. BLM treatment has identified side 
effects of skin edema, hyperpigmentation, and fibrosis124,125. Treatment with 1-100μg BLM either 
daily or on alternate days induces localized inflammation, dermal fibrosis, and loss of dermal 
adipose tissue, which lasts 6 weeks after injections123,126. In this model, dermal fibroblasts become 
activated, upregulate their expression of collagen, and increase ECM deposition at the site of 
injection127. Lung fibrosis is also evident at 3 weeks, even prior to cutaneous fibrosis, confirming 
the systemic induction of fibrosis126. BLM treatment also recapitulates other aspects of SSc 
including autoantibody formation and upregulation of inflammatory cytokines. Interestingly, skin 
changes are only localized to the area of injections and not to distant sites126. Absent from this 
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model, however, is the obliterative microangiopathy and perivascular inflammation that is also a 
defining feature of SSc128.  
 
Modifications of Yamamoto’s original protocol123 demonstrated no difference between daily or 
alternate day BLM treatments on dermal thickness; however, mice in the alternate day treatment 
regimen had increased collagen accumulation and number of myofibroblasts129. Comparison of 
BLM treatment in different mouse strains show C57BL/6 mice more sensitive to BLM compared 
to DBA/2129. There are also gender-dependent differences with male mice of all strains 
demonstrating more severe phenotypes129. This parallels SSc where there is a predilection for 
women but more severe disease phenotype and association with systemic involvement in 
men130,131.   
Other mouse models of SSc include the tight skin-1 mouse, which contains a mutation of the 
fibrillin-1 gene132, and tight skin-2 mouse, which is induced by the mutagenic agent 
ethylnitrosourea133. Both models, however, show thickening of the hypodermis instead of the 
dermis and do not accurately represent the histological skin changes in human SSc. The chronic 
graft-versus-host disease mouse model involves transplantation of immune competent cells from 
bone marrow and spleen cells into γ-irradiated mice to incite an alloreactive immune response134. 
While these mice exhibit many features of SSc including dermal fibrosis, dermal adipose loss, and 
pulmonary fibrosis, this model is technically difficult and requires specialized animal care for 
immunocompromised mice.  
The present study utilizes the BLM-induced murine model for systemic sclerosis based on the ease 
of induction of disease phenotype and well-representation within the existing literature allowing 
for the critical comparison of results.  
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1.6 Identifying the Problem 
The cutaneous manifestations of systemic sclerosis result from the aberrant deposition of extra-
cellular matrix components within the dermis and loss of the dermal adipose tissue. The 
progressive thickening and tightening of the skin lead to significant patient morbidity, with 
limitations in hand function, mouth opening, and facial expression. Rhamm, a receptor for HA, is 
transiently expressed in injured tissue and is hypothesized to generate the pro-fibrotic and anti-
adipogenic microenvironment in SSc. Novel Rhamm function-blocking peptides have been 
developed that attenuate fibrosis and promote adipogenesis in experimental models, opening a 
promising new avenue of exploration in the development of targeted treatments for systemic 
sclerosis.  
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2 Thesis Objectives and Aims  
 
The effects of the Rhamm function-blocking peptides, NPI-110 and NPI-106, were investigated in 
a bleomycin-induced mouse model of systemic sclerosis. Peptide treatment is hypothesized to 
attenuate dermal thickening and restore loss of dermal adipose tissue by redirecting the cellular 
microenvironment away from fibrogenesis and towards adipogenesis. Analysis of the peptide 
treatment effects and investigation of the regulatory pathways involved was performed through 
the three objectives outlined below.    
 
Objective 1: Determine the effect of peptides NPI-110 and NPI-106 on fibrosis in a 
bleomycin-induced murine model of systemic sclerosis  
BLM-treatment produces dermal thickening and increases collagen deposition. The anti-fibrotic 
effects of the peptides were examined through measurements of body weight changes, dermal 
thickness, and collagen density, bundling, and mRNA expression.  
 Aim 1: Determine effect of NPI-110 and NPI-106 treatment on body weight  
Aim 2: Quantify the effect of NPI-110 and NPI-106 on dermal thickness using Masson’s 
trichrome stained paraffin-processed skin samples 
Aim 3: Assess the effect of NPI-110 and NPI-106 on collagen density, bundling, and gene 
expression using polarized microscopy of Picrosirius Red birefringence and RT-PCR 
analysis of Col1a1 and Col3a1 expression  
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Objective 2: Determine the effect of peptides NPI-110 and NPI-106 on adipogenesis in a 
bleomycin-induced murine model of systemic sclerosis 
BLM-treatment causes loss of dermal adipose tissue. The adipogenic effects of the peptides were 
examined through measurements of dermal adipose thickness and analysis of adiponectin protein 
and perilipin mRNA expression.  
Aim 1: Quantify the effect of NPI-110 and NPI-106 on dermal adipose thickness using 
Masson’s trichrome stained paraffin-processed skin samples 
Aim 2: Determine the effect NPI-110 and NPI-106 on adiponectin protein expression using 
immunohistochemistry of paraffin-processed skin samples 
Aim 3: Determine the effect of NPI-110 and NPI-106 on adipogenesis through RT-PCR 
analysis of the adipogenic marker, perilipin.  
 
Objective 3: Elucidate the mechanism by which NPI-110 and NPI-106 affect fibrosis and 
adipogenesis in a bleomycin-induced murine model of systemic sclerosis  
Transcriptional profile analysis of peptide treatment compared to BLM-treatment was performed 
to identify potential interacting pathways. Genes of interest, including c-Myc, Tgfb1, and Rhamm 
were confirmed with RT-PCR. 
Aim 1: Profile 84 fibrosis-pathway specific and 84 adipogenesis-pathway specific genes 
and use bioinformatic analysis to identify genes of interest  
Aim 2: Confirm the identified genes of interest (Tgfb1, c-Myc) with RT-PCR analysis and 
immunohistochemistry of paraffin-processed skin samples   
Aim 3: Determine the effect of NPI-110 and NPI-106 treatment on Rhamm mRNA levels 
with RT-PCR analysis  
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3 Methods 
 
3.1 Injectable peptide NPI-110 and NPI-106 Formulations 
The HA-binding peptide NPI-106 (peptide sequence RGGRGRRR) and the RHAMM-binding 
peptide NPI-110 (peptide sequence 644KLKDENSQLKSEVSK) were synthesized and purified to 
>95% purity (gift from Dr. L. Luyt, Western University, London, Canada and Eravon 
Pharmaceuticals Inc). Peptides were dissolved in PBS and then filter sterilized through a 0.22μm 
filter.  
 
3.2 Animal Studies 
Animal studies were conducted by Stelic MC, Inc. (Tokyo, Japan) under the direction of Dr. 
Yuichiro Shibazaki. All experiments were approved and compliant with the Act of Welfare and 
Management of Animals, Standards Relating to the Care and Management of Animals and Relief 
of Pain (Ministry of the Environment, Act No. 105 and No. 88), and the Guidelines for Proper 
Conduct of Animal Experiments (Science Council of Japan).  
 
3.2.1 Animal Care  
Forty-eight six-week-old female C57BL/6J mice (Japan SLC, Japan) were used for the study. Mice 
were housed in TPX cages (CLEA Japan) with 6 mice per cage within a temperature-controlled 
room with a standard 12-hour light and dark cycle. Sterilized Paper-Clean bedding was provided 
and changed weekly. Each mouse was identified with a unique study number engraved on earrings. 
Sterilized normal mouse diet was provided ad libitum in a metal lid on top of the cage and on the 
floor. Distilled water was provided ad libitum from a water bottle with sipper tube that was 
replaced weekly. Mice were weighed daily and monitored for viability and any clinical signs of 
deterioration. 
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3.2.2 Mouse Treatment Groups 
Forty-eight mice were randomized into four treatment groups as outlined below in Table 1. A 
murine model of bleomycin-induced scleroderma was established based on a modified version of 
the Yamamoto protocol123. The dorsal backs of all mice where shaved using a razor prior to 
injections. Twelve mice were administered 1μg/μL bleomycin (Lot #15180, Nippon Kayaku, 
Japan) in 0.9% saline subcutaneously to the dorsal back at a dose of 50μg per mouse on alternate 
days, starting on day 0. In the control group, twelve mice were subcutaneously administered an 
equal volume of 50μL 0.9% saline to the dorsal back on alternate days, starting on day 0.  
Two peptides (NPI-110 and NPI-106) were tested. Twelve mice were administered subcutaneous 
bleomycin injections on alternate days as above and then administered 3mg/kg of Peptide NPI-
110 by subcutaneous injection every fourth day starting on day 0 (day 0, 4, 8, 12, 16, 20, 24). 
Twelve mice were administered bleomycin on alternate days as above and then administered 
3mg/kg of Peptide NPI-106 every fourth day starting on day 0 (day 0, 4, 8, 12, 16, 20, 24).  
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Treatment 
Group 
Number of 
Mice 
Treatment 
Bleomycin 12 
50uL (1μg/μL) of BLM administered subcutaneously on 
alternate days  
(Day 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26) 
Control 12 
50μL of 0.9% saline administered subcutaneously on 
alternate days  
(Day 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26) 
Peptide NPI-110 12 
50uL (1μg/μL) of BLM administered subcutaneously on 
alternate days  
(Day 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26) 
 
3mg/kg of Peptide NPI-110 administered every fourth day 
after BLM injections (Days 0, 4, 8, 12, 16, 20, 24) 
Peptide NPI-106 12 
50uL (1μg/μL) of BLM administered subcutaneously on 
alternate days  
(Day 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26) 
 
3mg/kg of Peptide NPI-106 administered every fourth day 
after BLM injections (Days 0, 4, 8, 12, 16, 20, 24) 
 
Table 1. Study protocol treatment groups  
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3.2.3 Tissue Collection 
All mice were euthanized on day 28 under pentobarbital sodium anesthesia by exsanguination 
through the abdominal aorta. Full thickness skin biopsies of the dorsal back within the area of 
injections were collected from each mouse. A portion of skin tissue was fixed in 10% neutral 
buffered formalin prior to embedding in paraffin wax for preparation of histologic sections. The 
remaining portion was placed into microcentrifuge tubes, snap frozen, and stored at -80oC.  
 
3.3 Effect of Peptide NPI-110 and NPI-106 on Fibrosis  
3.3.1 Effect of peptides on body weight  
Mice from each group were weighed daily starting on Day 0 and their weight was recorded at 
each time point as a percent of their starting Day 0 weight.  
 
3.3.2 Effect of peptides on dermal thickness  
3.3.2.1 Masson’s Trichrome Staining 
4μm paraffin-processed histology slides were prepared from mouse skin samples from each of the 
four treatment groups using a Microm HM 200 Ergostar Microtome (GMI; Ramsey, Minnesota). 
Paraffin-processed sections were stained with hematoxylin and eosin and Masson’s Trichrome 
according to manufacturer’s instructions (Sigma-Aldrich, St.Louis, Missouri) by Stelic MC, Inc.   
 
3.3.2.2 Quantification of dermal thickness 
Masson’s Trichrome stained slides of mouse skin sections were digitized using the Aperio 
Scanscope (Leica Biosystems, Wetzlar, Germany) and viewed using the Aperio ImageScope 
Viewer (Aperio ePathology Solutions; http://www.aperio.com) at 10X magnification. Dermal 
thickness was measured from the epidermal-dermal junction to the dermal-adipose junction. Three 
representative sections from twelve mice per treatment group were used for analysis. Three 
random measurements were taken per section by an independent blinded observer.  
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3.3.3. Effect of peptides on collagen density, bundling, and gene expression 
3.3.3.1 Picrosirius Red staining   
Paraffin-embedded mouse skin sections were stained for Picrosirius Red according to 
manufacturer’s instructions (Polysciences, Warrington, PA) with the help of Robarts Research 
Institute. Representative sections from seven mice from each of the four treatment groups were 
stained and used for analysis.  
 
3.3.3.2 Quantification of area fraction of collagen 
Picrosirius Red stained sections were viewed using a polarized microscope equipped with a 
circular polarizer and interference filters (Olympus BX51, Cambridge Research & 
Instrumentation, Woburn, MA, USA) and images were acquired using Abrio LC-PolScope 
processing software (Woburn, MA, USA) at 10X magnification. Three images were taken per slide 
by an independent blinded observer. Images were exported as .TIFF files in RGB format and then 
imported into ImageJ 1.47 (NIH; https://imagej.nih.gov/ij/). Collagen fibrils appear white under 
polarized microscopy, and the collagen density was calculated as the number of collagen fibril 
pixels within a defined area of dermis. The dermis was outlined using freehand selection and this 
area was calculated in square pixels. The thresholding function was executed with a lower limit of 
45 and upper limit of 255. This threshold was first defined using several test slides to determine 
the optimal setting for accurate isolation of the collagen fibrils. Once this was defined, the same 
threshold was used for analysis of all subsequent slides. The collagen density was calculated as 
below. 
        Area fraction of collagen = 
                                    
                          
  
 
3.3.3.3 Quantification of collagen bundling 
Picrosirius Red stained slides were also viewed using polarized microscopy with pseudo-colour 
channels applied to assess the density of collagen bundling. With this method, red indicates area 
of denser collagen bundling and blue indicates area of less dense collagen bundling135. The same 
captured images from 3.3.3.2 were viewed with pseudo-colour channels applied with an intensity 
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range for live image capture at 99.6 nm. Images were exported as .TIFF files in RGB format and 
then imported into Photoshop CC (Adobe, Mountain View, California). Overall collagen bundling 
was assessed by analyzing the red to blue color ratio within a defined dermal area. The dermis was 
outlined using freehand selection and this area was calculated in square pixels. Red and blue 
colored pixels within this area were isolated according to RGB channels and the mean intensity 
(out of 255) was calculated for each colour. The total number of red pixels and blue pixels were 
counted within the outlined dermal area and then multiplied by the mean intensity of that color to 
obtain absolute measurements as below.  
Red/blue expression = 
                                
                                 
  
 
3.3.3.4 RT-PCR analysis of Col1a1 and Col3a1 mRNA expression  
The mRNA expression of Col1a1 and Col3a1 of five mice from each of the four treatment groups 
was assayed by RT-PCR using the primers for Col1a1 and Col3a1 listed in Table 2. Skin biopsy 
samples were homogenized on ice in 600 μL of Trizol (Thermo-Fisher, Waltham, MA) in a 
microcentrifuge tube using the Ika T8 Ultra Turrax Homogenizer (Ika Works Inc, Wilmington, 
NC). Once tissues were adequately homogenized, an additional 400 μL of Trizol was added. RNA 
was extracted using the Trizol-chloroform liquid-liquid method136. 200 μL of chloroform was 
added to the sample and then vortexed for 10 seconds prior to centrifuging at 4oC for 15 minutes 
at 12 000 rpm (Sorvall Legend Micro 21R, Thermo Fisher Scientific, Waltham, MA). The top 
aqueous layer was then transferred into a new microcentrifuge tube without touching the liquid 
interface and the bottom layer was discarded. RNA was precipitated with the addition of 0.5 mL 
of pure isopropanol to each sample and then kept on ice for 10 minutes prior to centrifugation at 
4oC for 15 minutes at 12 000 rpm. The supernatant was removed and the RNA pellet washed with 
1mL of cold 70% ethanol three times with centrifugation at 4oC for 15 minutes at 7500 rpm in 
between each wash. The 70% ethanol was removed and pellet left to dry in a fume hood for 30 
minutes. The RNA pellet was resuspended in 20 μL of UltraPure RNAse-free distilled water 
(Invitrogen, Carlsbad, CA) and quantified using the NanoDrop One/OneC (Thermo-Fisher, 
Waltham, MA). RNA was stored at -80oC and only RNA samples with A260/280 > 1.8 and 
A260/230 > 1.7 were used for further experiments.  
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Reverse transcription was performed using the SuperScript VILO cDNA Mastermix (Thermo-
Fischer, Waltham, MA) according to manufacturer’s instructions. Complementary cDNA was 
generated from 1 μg RNA per sample. In addition to this amount of RNA, each reaction mixture 
contained 4 μL 5x VILO Reaction Mix, 2 μL of 10x Superscript Enzyme Mix, and enough 
Ultrapure RNA-ase free distilled water to make a total reaction volume of 20 μL. The reaction 
mixture was incubated at room temperature for 10 minutes and then in a 42oC water bath for 60 
minutes. The reaction was stopped at 85oC in a heat block for 5 minutes. cDNA was then diluted 
1:10 in 180 μL of Ultrapure distilled water and stored at -20oC until further use.  
RT-PCR was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-rad, 
Hercules, CA). Each reaction consisted of 8 μL of cDNA, 10 μL of SYBR Green Mastermix, and 
1 μL each of forward and reverse primer (Table 2) to make a total reaction volume of 20 μL. 
Reactions were prepared in a 96-well plate. RT-PCR experiments were performed using the 
Stratagene Mx3000P system (Agilent Technologies, Santa Clara, CA) with amplication profile of 
10 minutes 95oC, 40 cycles of 30 seconds at 95oC, 1 minute at 60oC, and 1 minute at 72oC.  
Analysis was performed using 5 mice from each of the four treatment groups and five technical 
replicates. Data was analyzed with a non-adaptive baseline starting from cycle two to two cycles 
before the earliest amplification observed. Threshold values were defined manually in log view 
and placed above the background signal but within the lower third of the linear phase of 
amplification plot. The same threshold value was used for each set of experiments. CT values were 
exported as a text file into Excel and analyzed using 2-ΔΔCt method 137 with standard propagation 
of errors. Data was normalized to Gapdh and compared to control normal saline treated mouse and 
expressed as fold change in Col1a1 and Col3a1 expression. The Col1a1:Col3a1 ratio was 
calculated as below with standard propagation of errors.   
 
Col1a1:Col3a1 ratio = Avg 2-ΔΔCt Col1a1 / Avg 2-ΔΔCt Col3a1 
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 Table 2. RT-PCR Primers  
  
 
Gene 
 
Forward Primer 
 
Reverse Primer 
 
Gapdh 
 
AAGGTCATCCCAGAGCTGAA 
 
CTGCTTCACCACCTTCTTGA 
 
 
Col1a1 
 
TGACTGGAAGAGCGGAGAGT 
 
 
ATCCATCGGTCATGCTCTCT 
 
Col3a1 
 
CTGTAACATGGAAACTGGGGAAA 
 
 
CCATAGCTGAACTGAAAACCACC 
 
Tgfb1 
 
CTCCCGTGGCTTCTAGTGC 
 
 
GCCTTAGTTTGGACAGGATCTG 
 
 
Rhamm 
 
CCTTGCTTGCTTCGGCTAAAA 
 
 
AGCAAAGCTCAATGCAGCAG 
 
c-Myc 
 
CTGTACCTCGTCCGATTCCAC 
 
 
TTCTTGCTCTTCTTCAGAGTCG 
 
 
Plin 
 
ACTCTCCGGAACACCATCT 
 
CCACAGTGTCTACCACGTTATC 
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3.4 Effect of Peptide NPI-110 and NPI-106 on Adipogenesis  
3.4.1 Effect of peptides on dermal adipose thickness  
Masson’s Trichrome stained slides of mouse skin biopsies were viewed using the Aperio 
ImageScope Viewer at 10X magnification. Dermal adipose tissue thickness was measured from 
the dermal-adipose tissue junction to the adipose-panniculus carnosus junction or the farthest 
extent of the adipose tissue when muscle not identifiable.   Three representative skin sections from 
twelve mice per treatment group were used for analysis. Three random measurements were taken 
per section by an independent blinded observer.  
 
3.4.2 Effect of peptides on adiponectin protein expression  
4 μm sections from paraffin-embedded mouse skin samples were prepared onto glass slides with 
two skin sections per slide. Sections were then deparaffinized with two 15-minute xylene washes 
and then rehydrated with a descending alcohol series of 100%, 95%, 70% ethanol, followed by 
distilled water and PBS, pH 7.4, washes. Antigen retrieval was performed in 10 mM sodium citrate, 
pH 6.4, with an inverter microwave (Panasonic, Kadoma, Osaka) for 3 minutes at maximum 
power, 5 minutes at medium power, and 8 minutes at low power. Extra 10 mM sodium citrate 
solution was added with ongoing evaporation to ensure tissues were covered at all times. 
Endogenous peroxidase activity was then blocked with 3.0% H2O2 diluted in PBS for 10 minutes, 
rinses with PBS, and then 3.0% BSA diluted in PBS for 2 hours.  A pen with hydrophobic ink was 
then used to trace around the two skin sections. Slides were incubated with rabbit polyclonal anti-
adiponectin antibody (ab216502, Abcam) at 1:600 diluted in 1% BSA overnight at 4oC. Each slide 
contained a negative control of isotype matched non-immune rabbit IgG (DAKO Agilent, Santa 
Clara, CA). The following day, slides were washed in PBS prior to incubation with biotin-
conjugated goat anti-rabbit secondary IgG (Vector Labs, Burlington, ON) at 1:500 dilution in PBS 
for 2 hours at room temperature. Streptavidin-horseradish peroxidase (ab7403, Abcam) diluted 
1:2000 in PBS was then applied to each section and incubated for 30 minutes at room temperature. 
Diaminobenzidine (DAKO Liquid DAB Substrate+ Chromogen system, Agilent, Santa Clara, CA) 
was applied for 5 minutes to visualize staining and then washed in PBS. Sections were 
counterstained with hematoxylin prior to washing in an ascending ethanol series (70%, 95%, 100% 
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ethanol), and then cleared with xylene. Slides were mounted with Cytoseal-60 (Thermo Fisher, 
Waltham, MA) and a glass slide and left overnight to dry with protection against ambient light.   
Immunohistochemical analysis of adiponectin was performed by digitizing the slides using the 
Scanscope at 10X magnification and importing .TIFF file images into ImageJ 1.47. Representative 
sections from three mice per treatment group were used for analysis, with three high powered field 
sections per slide and three separate slides per mouse. In the ImageJ software, free-hand selections 
were used to remove the epidermis and hair follicles, which uniformly stained positive for 
adiponectin in all treatment groups. The area of the remaining region was calculated. The image 
was then deconvoluted with the ‘H-DAB’ setting with conservative thresholds for brown pixels at 
165 units and blue pixels at 240 units. The number of positively stained brown pixels per mm2 was 
then recorded for each section.  
 
3.4.3 Effect of peptides on perilipin mRNA expression  
Perilipin mRNA expression in mouse skin biopsy tissues was assayed by RT-PCR as previously 
described in section 3.3.3.4 using primers listed in Table 2. Analysis was performed using three 
mice from each treatment group and five technical replicates. Data was exported to Excel and 
analyzed using 2-ΔΔCt method normalized to Gapdh and compared to control normal saline treated 
mouse. Data expressed as fold change in Plin mRNA expression.   
 
3.5 Elucidating the Mechanism of NPI-110 and NPI-106 Function 
3.5.1 Bioinformatic analysis of expression of 84 fibrosis and 84 adipogenesis-pathway specific 
genes 
3.5.1.1 RT2 Profiler PCR Mouse Fibrosis Array 
The expression of 84 fibrosis pathway-focused genes (Figure 2) was profiled using the 96-well 
RT2 Profiler PCR Plate Array (Qiagen, Hilden, Germany). RNA was isolated from mouse skin 
biopsy tissues as outlined in 3.3.3.4 using the Trizol-chloroform liquid-liquid extraction method. 
As a screening array, experiments were performed with one technical replicate from one mouse 
from each of the four treatment groups. 2 μg of RNA was reverse transcribed to cDNA using the 
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RT2 First Strand Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. A 
mastermix of 1350 μL of RT2 SYBR Green Mastermix, 102 μL of the cDNA synthesis reaction, 
and 1248 μL of Ultrapure distilled water was first prepared. 25 μL of this mastermix was added to 
each well of RT2 Profiler PCR Mouse Fibrosis Array (PAMM-120Z, Qiagen, Hilden, Germany) 
and sealed with optical thin-wall 8-cap strips. PCR was run using the Stratagene Mx3000P system 
(Agilent Technologies, Santa Clara, CA). Data was exported to Excel after setting a non-adaptive 
baseline and manual thresholding. Data was then analyzed using the SABiosciences PCR array 
data analysis software (Qiagen, www.SABiosciences.com/pcrarraydataanalysis.php) using the 2-
ΔΔCt method normalized to Gapdh and compared to the BLM-treated mouse.  
 
3.5.1.2 RT2 Profiler PCR Mouse Adipogenesis Array 
To elucidate the mechanism by which NPI-110 and NPI-106 affect adipogenesis, expression of 84 
adipogenesis pathway-focused genes (Figure 3) were profiled using the 96-well RT2 Profiler PCR 
Mouse Adipogenesis Array (PAMM-049A, Qiagen, Hilden, Germany). Experiments were 
performed with one mouse from each of the four treatment groups and analyzed as in 3.5.1.1.  
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Figure 2. Fibrosis pathway-focused 96-well plate set-up. Layout of 96-well RT2 Profiler PCR 
Mouse Fibrosis Array (Qiagen, Hilden, Germany) profiling 84 different genes. Full gene list in 
Supplementary Table 1. RTC, reverse transcriptase control; PPC, positive PCR control.  
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Figure 3. Adipogenesis pathway-focused 96-well plate set-up. Layout of 96-well RT2 Profiler PCR 
Mouse Adipogenesis Array (Qiagen, Hilden, Germany) profiling 84 different genes. Full gene list in 
Supplementary Table 2.  RTC, reverse transcriptase control; PPC, positive PCR control.  
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3.5.1.3 Bioinformatic Analysis  
Ingenuity Pathway Analysis Software (Qiagen Bioinformatics, Hilden, Germany) was used to 
compare the transcriptional profiles of NPI-110 and NPI-106 treatment with that of BLM-
treatment alone. The core analysis was performed using fold-expression values of each assayed 
gene from the RT2 Profiler Fibrosis and Adipogenesis arrays with strict criteria for a fold change 
> 1.5 for upregulated and down-regulated genes. Causal pathway analysis was performed for 
canonical pathways and upstream regulators.   
 
3.5.1.4 Confirmation of Tgfb1 mRNA expression with RT-PCR  
IPA upstream regulator analysis indicated Tgfb1 as the top most predicted regulator and these 
results were confirmed with RT-PCR analysis using primers for Tgfb1 as listed in Table 2. 
Analysis was performed as in 3.3.3.1 using three mice from each treatment group and five technical 
replicates. Data was exported to Excel and analyzed using 2-ΔΔCt method normalized to Gapdh and 
compared to control normal saline treated mouse. Data expressed as fold change in Tgfb1 
expression.   
 
3.5.1.5 TGFβ1 Immunohistochemistry 
4 μm sections from paraffin-embedded skin samples were used for immunohistochemistry staining 
for total Tgfb1 with antigen retrieval and blocking performed in the same manner as in 3.4.2. Slides 
were then incubated with anti-Tgfb1 antibody (ab92486, Abcam) at 1:600 dilution in 1% BSA 
overnight, washed in PBS, and then incubated with biotin-conjugated goat anti-rabbit secondary 
IgG (Vector Labs, Burlington, ON) 1:500 dilution for 2 hours. Each slide contained a negative 
control of isotype matched non-immune rabbit IgG (DAKO Agilent, Santa Clara, CA). 
Streptavidin-horseradish peroxidase diluted 1:2000 in PBS was applied to each section for 30 
minutes at room temperature. Colorimetric detection was then performed with diaminobenzidine 
(DAKO Liquid DAB Substrate+ Chromogen system, Agilent, Santa Clara, CA) applied for 5 
minutes. Sections were counterstained with hematoxylin, taken through an ascending ethanol 
series, cleared with xylene, and then mounted with Cytoseal-60 (Thermo Fisher, Waltham, MA) 
30 
 
and a glass slide. Sections were dried overnight with protection against ambient light prior to 
analysis.  
Analysis of total Tgfb1 staining was performed by digitizing the slides using the Scanscope at 10X 
magnification and importing .TIFF file images into ImageJ 1.47. Representative sections from 
three mice per treatment group were used for analysis, with three high powered field magnification 
sections per slide and three separate slides per mouse. In ImageJ software, free-hand selections 
were used to isolate the dermal layer and dermal adipose tissue layer for separate analysis. The 
area of the selected area was recorded in mm2. Using the counting function, the number of 
positively stained cells within the selected area was counted manually and recorded to calculate 
the number of positive cells/mm2. This was repeated for the dermal adipose tissue layer.  
 
3.5.1.6 Confirmation of c-Myc mRNA expression with RT-PCR  
Myc gene expression was found to be down-regulated with both NPI-110 and NPI-106 peptide 
treatment in the fibrosis-specific gene panel. IPA canonical pathway analysis further identified c-
Myc as a potential regulator of NPI-110 and NPI-106 peptide function. This was further confirmed 
with RT-PCR analysis using the primers for c-Myc listed in Table 2. Analysis was performed as 
in 3.3.3.1 using three mice from each treatment group and five technical replicates. Data was 
exported to Excel and analyzed using 2-ΔΔCt method normalized to Gapdh and compared to control 
normal saline treated mouse. Data expressed as fold change in c-Myc expression.   
 
3.5.1.7 c-Myc Immunohistochemistry 
4 μm sections from paraffin-embedded skin samples were used for immunohistochemistry staining 
for c-Myc with antigen retrieval and blocking performed in the same manner as in 3.4.2. Slides 
were then incubated with recombinant rabbit monoclonal anti-c-Myc antibody (ab32072, Abcam) 
at 5 ug/mL dilution in 1% BSA overnight, washed in PBS, and then incubated with biotin-
conjugated goat anti-rabbit secondary IgG (Vector Labs, Burlington, ON) diluted 1:500 for 2 
hours. Each slide contained a negative control of isotype matched non-immune rabbit IgG (DAKO 
Agilent, Santa Clara, CA). Streptavidin-horseradish peroxidase diluted 1:2000 in PBS was applied 
to each section for 30 minutes at room temperature and then colorimetric detection performed with 
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diaminobenzidine (DAKO Liquid DAB Substrate+ Chromogen system, Agilent, Santa Clara, CA) 
applied for 5 minutes. Sections were counterstained with hematoxylin, taken through an ascending 
ethanol series, cleared with xylene, and then mounted with Cytoseal-60 (Thermo Fisher, Waltham, 
MA) and a glass slide. Sections were dried overnight with protection against ambient light prior 
to analysis.  
Immunohistochemical analysis of c-Myc was performed in the same manner as in 3.4.2 with 
analysis of .TIFF file images using ImageJ 1.47 with representative sections from five mice per 
treatment group and three high power field sections per slide. Free-hand selections were used to 
remove the epidermis and hair follicles and image deconvolution with the ‘H-DAB’ setting was 
used to record the number of positively stained brown pixels per mm2. 
 
3.5.2 Effect of peptide on Rhamm mRNA expression  
Rhamm mRNA expression was confirmed with RT-PCR analysis using primers for Rhamm as 
listed in Table 2. Analysis was performed as in 3.3.3.1 using three mice from each treatment group 
and five technical replicates. Data was exported to Excel and analyzed using 2-ΔΔCt method 
normalized to Gapdh and compared to control normal saline treated mouse. Data expressed as fold 
change in Rhamm mRNA expression.   
 
 
3.6 Statistical Analysis 
Data recorded in Excel was imported into SPSS Statistics 25 (IBM, Armonk, NY) and tested for 
normality using the Shapiro-Wilk test. Statistical analysis was performed for parametric data using 
one-way ANOVA to compare means between all four treatment groups and post-hoc analysis with 
Fisher’s least significant difference (LSD) test. Non-parametric data was analyzed using the 
Kruskall-Wallis test with post-hoc Mann-Whitney U with Bonferroni correction for repeated 
comparisons. Significance was set at p < 0.05. 
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4 Results 
 
The BLM-induced systemic sclerosis mouse model is well-established to recapitulate the early 
inflammatory phase of scleroderma, which is associated with increased serum HA in SSc 
patients92–94. The effects of the novel Rhamm-binding peptide (NPI-110) and the HA-binding 
peptide (NPI-106) were tested in a mouse model of BLM-induced systemic sclerosis. C57BL/6J 
mice, injected subcutaneously with bleomycin on alternate days, were treated with either NPI-110 
or NPI-106 to determine the ability of the peptides attenuate Rhamm-directed signalling of 
fibrogenesis and to promote adipogenesis.  
There were no differences in mortality between the four treatment groups, and all forty-eight mice 
survived until day 28. Weights were recorded daily and BLM-treated mice did not gain weight at 
the same rate as compared to control mice. This difference was significant by day 9 and persisted 
until day 28. (p < 0.0001) (Figure 4). Neither peptide was able to restore normal weight gain at 
any time point.  
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Figure 4. Peptide NPI-110 and NPI-106 treatment does not restore normal weight gain. 
Weekly body weights of mice in each of the four treatment groups expressed as a percentage of 
baseline body weight on day 0. * indicates time points of statistically significant differences 
between BLM-treated and control groups (p < 0.0001). Values represent mean and SEM with 
analysis of 12 mice per treatment group. Analysis with one-way ANOVA and post-hoc LSD test 
for significance.  Data and figure provided by Stelic MC.  
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Mouse skin biopsy samples were visualized with H&E and Masson’s Trichrome to determine if 
peptide treatments ameliorated BLM-induced fibrosis, as measured by dermal thickness, collagen 
bundling and density, and Col1a1 and Col3a1 mRNA expression.   
 
Masson’s trichrome stains collagen blue and in the BLM treatment group, there is thickening of 
the dermal layer and replacement of normal tissues with collagen. Visually, both peptide 
treatments blunted the accumulation of collagen within the dermis (Figure 5A).  This was 
quantified with measurements of dermal thickness from the epidermal-dermal junction to the 
dermal-adipose tissue junction. BLM-injection caused a 25% increase in dermal thickness 
compared to control (p < 0.0001). This was significantly decreased by 6% with both peptide 
treatments compared to BLM treatment (NPI-110 p = 0.004, NPI-106 p = 0.006); however, neither 
peptide was able restore dermal thickness back to baseline.  
 
Given the increased dermal thickness, the architecture and density of collagen bundling was 
investigated with Picrosirius Red stained paraffin-processed slides. Picrosirius Red stains collagen 
fibres red, and when viewed in brightfield microscopy, highly cross-linked collagen fibres produce 
a stronger red staining pattern135,138. Collagen in lesional skin treated with BLM stained intensely 
red, whereas peptide treatment resulted in weaker-staining, less cross-linked fibres (Figure 6A). 
Viewed under polarized microscopy, collagen fibers in lesional BLM-treated skin demonstrate 
strong birefringence (Figure 6A) with collagen fibres appearing white. The area fraction of 
collagen was calculated as a measurement of collagen content. BLM treatment induced a 24% 
increase in the area fraction of collagen (p < 0.001) compared to control. While peptide NPI-110 
decreased the area fraction of collagen (p = 0.039), treatment with peptide NPI-106 did not have a 
significant effect (p = 0.53). The density of collagen accumulation within the dermis was assayed 
with the application of pseudo-color channels during polarized microscopy. With this technique, 
densely packed collagen fibrils appear red and loosely packed collagen appears blue (Figure 7A). 
The proportional area of densely-packed collagen was quantified with calculations of the red/blue 
colour fraction, which was more than two-fold higher in BLM treated skin compared to control 
(Figure 7B), reflecting accumulation of densely packed collagen. However, there was no 
significant effect of NPI-110 or NPI-106 treatment on collagen density as measured by the red/blue 
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colour fraction. These findings suggest that peptide NPI-110 treatment reduced dermal thickness 
and collagen content in BLM-induced SSc. Peptide NPI-106 was not effective in ameliorating 
these BLM-induced fibrotic changes.  
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Figure 5. Peptide NPI-110 and NPI-106 reduces collagen deposition and dermal thickening. 
(A) Paraffin processed histology sections of mice from all four treatment groups stained for H&E 
and Masson’s Trichrome to visualize tissue architecture and collagen distribution. (B) 
Quantification of dermal thickness with measurements from the epidermal-dermal junction to the 
dermal-adipose junction. Values represent mean and SEM from three random measurements in 
three sections per mouse, 12 mice per treatment group. Analysis with Kruskall-Wallis test with 
post-hoc Mann-Whitney U with Bonferroni correction. (* p < 0.05, ***p < 0.0001).  
A
B
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Figure 6. Peptide NPI-110 but not NPI-106 reduces the area fraction of collagen. (A) 
Picrosirius Red stained paraffin-processed histology sections of mice from four treatment groups 
on day 28 visualized with brightfield (top) and polarized (bottom) microscopy. (B) Calculated area 
fraction of collagen. Values represent mean and SEM of three random sections per slide, three 
slides per mouse, and 7 mice per group. Analysis with one-way ANOVA and post-hoc LSD test 
for significance. (* p < 0.05, ***p < 0.0001).  
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Figure 7.  Neither NPI-110 or NPI-106 reduces collagen density to baseline. (A) Picrosirius 
Red stained paraffin-processed histology sections of mice from all four treatment groups on day 
28 visualized with polarized microscopy and pseudo-colour channels.  Red color indicates more 
densely packed collagen fibrils and blue highlight more loosely packed collagen. (B) 
Quantification of collagen density with red-to-blue color ratio. Values represent mean and SEM 
of three random sections per slide, three slides per mouse, and 7 mice per group. Analysis with 
Kruskall-Wallis test with post-hoc Mann-Whitney U with Bonferroni correction. (**p < 0.001).  
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To further characterize the type of collagen accumulating within the dermis, Col1a1 and Col3a1 
mRNA expression was examined with RT-PCR. Clinically, SSc is characterized by the increased 
deposition of type 1 collagen in the extracellular matrix139,140 and RT-PCR analysis confirmed this 
in the BLM-induced SSc model with a statistically significant 1.22-fold increase in Col1a1 mRNA 
expression  (p = 0.03) compared to control. Both peptides demonstrated potent effects in 
suppressing type 1 collagen expression significantly below baseline, with NPI-110 and NPI-106 
decreasing Col1a1 expression by 11-fold (p < 0.0001) and 14-fold (p < 0.0001), respectively 
(Figure 8A). In contrast to type 1 collagen, type 3 collagen expression in lesional BLM-treated 
skin was decreased 2.5-fold (p < 0.0001) (Figure 8B). The concomitant increase in type 1 collagen 
and decrease in type 3 collagen resulted in a 3-fold increase in the Col11:Col3a1 ratio with BLM-
treatment (Figure 8C). Peptide NPI-110 treatment was able to ameliorate some of the loss of 
collagen 3 expression (p = 0.012); however, interestingly, NPI-106 treatment resulted in further 
decrease collagen 3 expression (p < 0.0001 compared to BLM-treatment) (Figure 8B). NPI-110 
treatment reduced the Col1a1:Col3a1 ratio below baseline (NPI-110 p < 0.0001 compared to 
control) while NPI-106 treatment normalized the Col11:Col3a1 ratio to control (Figure 8C).  
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 Figure 8. Peptide NPI-110 and NPI-106 suppress Col1a1 mRNA expression and reduce the 
Col1a1:Col3a1 ratio.  RT-PCR analysis of Col1a1 and (A) Col3a1 (B) mRNA expression in mice 
from each of the four treatment groups on day 28. Values represent mean and SEM of fold change 
from five mice per treatment group and five technical replicates.  Analysis with one-way ANOVA 
and post-hoc LSD test. (* p < 0.05, ** p < 0.001, **p < 0.0001).   
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The increase in dermal thickness and collagen content in SSc is at the expense of the dermal 
adipose tissue which is substantially decreased. BLM-treatment caused a 14% loss of dermal 
adipose tissue thickness (p = 0.001) (Figure 9). Treatment with either NPI-110 and NPI-106 was 
unable to ameliorate the detectable loss of dermal adipose tissue. 
Next, the effect of peptide treatment on adipokine expression was examined to see if they promoted 
a more favourable microenvironment that was supportive of adipogenesis. Immunohistochemical 
analysis of adiponectin, show that the loss of dermal adipose tissue thickness in BLM-injected skin 
is also reflected in a significant decrease in adiponectin expression (p < 0.0001) (Figure 10). 
Despite no measurable changes in dermal adipose thickness, NPI-110 treatment significantly 
increased adiponectin expression (p < 0.0001 compared to BLM-treatment) comparable to baseline 
levels (Figure 10B). There was no change in adiponectin expression with NPI-106 treatment (p = 
0.061) (Figure 10B).   
Perilipin mRNA expression was assayed as another measure of adipogenesis. Perilipin is a lipid 
droplet-binding protein that is highly expressed from adipocytes141. BLM treatment resulted in 7-
fold reduction in Plin mRNA expression and both peptide NPI-110 and NPI-106 treatments led to 
partial recovery of Plin mRNA expression to only a 2-fold reduction compared to baseline (Figure 
11).   
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Figure 9. Peptide NPI-110 and NPI-106 treatment does not ameliorate the detectable loss of 
dermal adipose tissue. Quantification of dermal adipose tissue thickness with measurements from 
Masson’s Trichrome stained paraffin-embedded slides from the epidermal-dermal junction to the 
adipose-panniculosus carnosus junction. Values representing mean and SEM from three random 
measurements in three sections per mouse, 12 mice per treatment group. Analysis with Kruskall-
Wallis test with post-hoc Mann-Whitney U with Bonferroni correction. (** p < 0.001).  
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Figure 10. Peptide NPI-110 treatment restores adiponectin protein expression. (A) Paraffin-
processed skin sections of mice from all four treatment groups at day 28 stained for anti-
adiponectin antibody. (B) Quantification of immunohistochemical staining for adiponectin. Values 
represent mean and SEM from three random measurements in three sections per mouse, 3 mice 
per treatment group. Analysis with one-way ANOVA and post-hoc LSD test for significance. (** 
p < 0.001, *** p < 0.0001).  
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Figure 11. Peptide NPI-110 and NPI-106 treatment partially restores Plin mRNA expression. 
RT-PCR performed on lesional skin from mice after 28 days of either BLM-treatment or BLM-
treatment with peptide injections, with saline injections as control. Values represent means and 
SEM from three mice per treatment group and five technical replicates. Analysis with one-way 
ANOVA and post-hoc LSD test. (* p < 0.05, *** p < 0.0001).   
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To elucidate the mechanisms by which NPI-110 and NPI-106 affect fibrosis and adipogenesis, 
transcriptional expression of 84 fibrosis-specific and 84 adipogenesis-specific genes were profiled. 
Fibrosis pathway related genes include ECM and cell adhesion molecules, inflammatory 
cytokines, growth factors, Tgfb1 superfamily members, and regulators of epithelial-to-
mesenchymal transition. Adipogenesis pathway related genes included adipokines, Ppary targets, 
Wnt family proteins, and adipogenesis regulators involved in white and brown adipose tissue 
development.  
The results of 29 selected fibrosis-pathway genes are shown (Figure 12A, full results of all genes 
in Supplementary Table 1). NPI-110 significantly reduced the expression of 22/84 fibrosis genes, 
including Myc which was decreased 196-fold with NPI-110 treatment but not with NPI-106. The 
results of 26 selected adipogenesis-pathway genes are shown (Figure 12B, full results of all genes 
in Supplementary Table 2). The majority of genes are down-regulated, including the pro-fibrotic 
genes fibroblast-growth factor 1, 2, and 10 which demonstrated up to 68.6-fold reduction with 
NPI-110 treatment. All members of the Wnt family assayed in the adipogenesis-specific pathway 
gene panel were suppressed by both NPI-110 and NPI-106 (Figure 12). NPI-110 induced a 50.9-
fold reduction in Wnt1, 68.6-fold reduction in Wnt3a and 55.7-fold reduction in Wnt5b. Wnt10b 
and Wnt5a were down-regulated 4.4 and 3.9-fold, respectively, with NPI-110 treatment. NPI-106 
also reduced Wnt expression although to a lesser degree. Ppary which is normally inhibited by 
Erk1 through Rhamm, was comparatively less suppressed, with only 2-fold reduction with peptide 
treatment, suggesting perhaps release of Erk1 inhibition.  This supports the hypothesis that the 
antifibrotic effects of peptide treatment may be able to create a more favourable microenvironment 
for adipogenesis to occur as indicated by increased expression of adipokines.   
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Figure 12. Transcriptional profiling of fibrosis-specific (A) and adipogenesis-specific (B) 
genes. Selected data of 29 fibrosis-specific genes (A) and 26 adipogenesis-specific genes (B) 
profiled by RT-PCR that are either upregulated or downregulated by NPI-110 (blue bars) or NPI-
106 (orange bars) with fold expression expressed relative to BLM-treated group. Full gene names 
and data in Supplementary Table 1 (Fibrosis) and Supplementary Table 2 (Adipogenesis). All data 
represent fold expression from one mouse per treatment group with one technical replicate.  
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Gene  Symbol NPI-110 NPI-106 
Acta2 Actin, alpha 2, smooth muscle, aorta -5.4 -3.7 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -1.6 -1.9 
Akt1 Thymoma viral proto-oncogene 1 2.7 -1.9 
Bcl2 B-cell leukemia/lymphoma 2 1.2 3.1 
Bmp7 Bone morphogenetic protein 7 2.7 -1.9 
Cav1 Caveolin 1, caveolae protein -1.3 -2.5 
Ccl11 Chemokine (C-C motif) ligand 11 -8.6 -2.9 
Ccl12 Chemokine (C-C motif) ligand 12 -21.0 -31.3 
Ccl3 Chemokine (C-C motif) ligand 3 -1.6 -6.1 
Ccr2 Chemokine (C-C motif) receptor 2 -3.7 -1.9 
Cepbp CCAAT/enhancer binding protein (C/EBP), beta -1.4 -1.3 
Col1a2 Collagen, type I, alpha 2 -5.6 -29.7 
Col3a1 Collagen, type III, alpha 1 -2.6 -34.1 
CTGF Connective tissue growth factor 2.6 -1.9 
Cxcr4 Chemokine (C-X-C motif) receptor 4 -16.1 -10.2 
Dcn Decorin -1.1 -77.2 
Edn1 Endothelin 1 -1.9 -1.9 
Egf Epidermal growth factor -6.6 -4.4 
Eng Endoglin -2.2 -1.5 
Fasl Fas ligand (TNF superfamily, member 6) -118.6 -19.4 
Grem1 Gremlin 1 -1.6 -1.9 
Hgf Hepatocyte growth factor -1.2 1.3 
Ifng Interferon gamma -3.8 1.3 
Il10 Interleukin 10 -1.6 -1.9 
Il13 Interleukin 13 -10.3 -16.0 
Il13ra2 Interleukin 13 receptor, alpha 2 -14.3 -6.0 
Il1a Interleukin 1 alpha 1.1 2.0 
Il1b Interleukin 1 beta 1.1 -1.9 
Il4 Interleukin 4 -1.2 -1.9 
Il5 Interleukin 5 -1.1 -1.9 
Ilk Integrin linked kinase 2.6 -1.9 
Inhbe Inhibin beta E -2.8 -1.9 
Itga1 Integrin alpha 1 2.8 1.5 
Itga2 Integrin alpha 2 1.0 -1.9 
Itga3 Integrin alpha 3 -1.1 -1.9 
Itgav Integrin alpha V 6.1 1.5 
Itgb1 Integrin beta 1 (fibronectin receptor beta) -2.6 -16.6 
Itgb3 Integrin beta 3 -1.6 -1.9 
Itgb5 Integrin beta 5 -2.5 -9.4 
Itgb6 Integrin beta 6 -6.2 -11.1 
Itgb8 Integrin beta 8 -1.8 -2.0 
Jun Jun oncogene 3.3 -1.9 
Lox Lysyl oxidase 1.7 -1.9 
Ltbp1 Latent transforming growth factor beta binding protein 1 1.0 1.8 
Mmp13 Matrix metallopeptidase 13 -2.7 1.2 
Mmp14 Matrix metallopeptidase 14 (membrane-inserted) 4.7 -1.9 
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Mmp1a Matrix metallopeptidase 1a (interstitial collagenase) 1.5 1.1 
Mmp2 Matrix metallopeptidase 2 1.3 -1.3 
Mmp3 Matrix metallopeptidase 3 -2.6 -2.5 
Mmp8 Matrix metallopeptidase 8 -7.9 3.1 
Mmp9 Matrix metallopeptidase 9 -1.9 -1.1 
Myc Myelocytomatosis oncogene -196.7 -15.6 
Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 1.3 -1.9 
Pdgfa Platelet derived growth factor, alpha -1.8 -1.9 
Pdgfb Platelet derived growth factor, B polypeptide -3.5 -2.6 
Plat Plasminogen activator, tissue 2.1 -1.9 
Plau Plasminogen activator, urokinase 1.4 -2.0 
Plg Plasminogen -1.5 -1.9 
Serpina1a Serine (or cysteine) peptidase inhibitor, clade A, member 1a -5.7 1.3 
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 -1.3 1.0 
Serpinh1 Serine (or cysteine) peptidase inhibitor, clade H, member 1 2.9 -4.1 
Smad2 MAD homolog 2 (Drosophila) 2.7 5.2 
Smad3 MAD homolog 3 (Drosophila) 1.8 -1.9 
Smad4 MAD homolog 4 (Drosophila) 1.0 -1.9 
Smad6 MAD homolog 6 (Drosophila) -1.8 -1.0 
Smad7 MAD homolog 7 (Drosophila) -1.7 1.2 
Snai1 Snail homolog 1 (Drosophila) -24.6 -1.9 
Sp1 Trans-acting transcription factor 1 1.3 1.2 
Stat1 Signal transducer and activator of transcription 1 -3.8 -67.6 
Stat6 Signal transducer and activator of transcription 6 -24.6 -1.9 
Tgfb1 Transforming growth factor, beta 1 2.0 -1.5 
Tgfb2 Transforming growth factor, beta 2 -2.0 -1.9 
Tgfb3 Transforming growth factor, beta 3 -3.6 -1.9 
Tgfbr1 Transforming growth factor, beta receptor I -5.0 -3.0 
Tgfbr2 Transforming growth factor, beta receptor II 2.4 -1.9 
Tgif1 TGFB-induced factor homeobox 1 -6.3 -1.9 
Thbs1 Thrombospondin 1 -1.2 -1.8 
Thbs2 Thrombospondin 2 -5.6 -32.4 
Timp1 Tissue inhibitor of metalloproteinase 1 -3.1 -7.2 
Timp2 Tissue inhibitor of metalloproteinase 2 -5.7 -107.6 
Timp3 Tissue inhibitor of metalloproteinase 3 6.3 -1.9 
Timp4 Tissue inhibitor of metalloproteinase 4 -1.8 -1.9 
Tnf Tumor necrosis factor 1.3 -1.9 
Vegfa Vascular endothelial growth factor A 1.8 4.7 
 
Supplementary Table 1. Expression of 84 fibrosis-pathway specific genes. Fold expression of 
84 fibrosis-specific genes with NPI-110 or NPI-106 peptide-treatment relative to BLM-treated 
group. Negative numbers indicate under-expression and positive numbers indicate over-expression 
of specific gene. Data represents RT-PCR analysis of mRNA from one mouse per treatment group 
with one technical replicate.  
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Gene Full Gene Name NPI-110 NPI-106 
Acacb Acetyl-Coenzyme A carboxylase beta -5.5 -15.6 
Adig Adipogenin -4.1 1.2 
Adipog Adiponectin, C1Q and collagen domain containing -23.8 -15.6 
Adrb2 Adrenergic receptor, beta 2 -7.1 -18.8 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -16.7 -15.6 
Angpt2 Angiopoietin 2 -1.4 -15.6 
Axin1 Axin 1 -3.7 -2.2 
Bmp2 Bone morphogenetic protein 2 -11.2 -6.3 
Bmp4 Bone morphogenetic protein 4 -2.4 -2.7 
Bmp7 Bone morphogenetic protein 7 -7.7 -15.6 
Ccnd1 Cyclin D1 -26.5 -27.7 
Cdk4 Cyclin-dependent kinase 4 -15.9 -42.2 
Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) -1.1 -4.5 
Cdkn1b Cyclin-dependent kinase inhibitor 1B -2.5 -15.6 
Cebpa CCAAT/enhancer binding protein (C/EBP), alpha -3.4 -16.0 
Cebpd CCAAT/enhancer binding protein (C/EBP), beta -6.5 -15.6 
Cebpd CCAAT/enhancer binding protein (C/EBP), delta -12.9 -15.6 
Cfd Complement factor D (adipsin) -18.4 -2.3 
Creb1 CAMP responsive element binding protein 1 -4.5 -10.2 
Ddit3 DNA-damage inducible transcript 3 -5.6 -8.1 
Dio2 Deiodinase, iodothyronine, type II -4.6 -6.2 
Dkk1 Dickkopf homolog 1 (Xenopus laevis) -3.8 -15.6 
Dlk1 Delta-like 1 homolog (Drosophila) -68.6 -15.6 
E2f1 E2F transcription factor 1 -9.6 -15.6 
Egr1 Early growth response 2 -9.3 -3.8 
Fabp4 Fatty acid binding protein 4, adipocyte -18.5 -3.4 
Fasn Fatty acid synthase -4.4 1.0 
Fgf1 Fibroblast growth factor 1 -15.5 -44.9 
Fgf10 Fibroblast growth factor 10 -68.6 -13.5 
Fgf2 Fibroblast growth factor 2 -4.1 -15.6 
Foxc2 Forkhead box C2 -14.7 -12.5 
Foxo1 Forkhead box O1 -4.7 -4.8 
Gata2 GATA binding protein 2 1.4 3.7 
Gata3 GATA binding protein 3 -68.6 -4.9 
Hes1 Hairy and enhancer of split 1 (Drosophila) -2.5 -15.6 
Insr Insulin receptor -8.3 -2.5 
Inr1 Insulin receptor substrate 1 -3.0 -15.6 
Inr2 Insulin receptor substrate 2 -4.1 -6.4 
Jun Jun oncogene -11.4 -78.8 
Klf15 Kruppel-like factor 15 -68.6 -1.7 
Klf2 Kruppel-like factor 2 (lung) -68.6 -15.6 
Klf3 Kruppel-like factor 3 (basic) -3.3 -15.6 
Klf4 Kruppel-like factor 4 (gut) 1.6 -15.6 
Lep Leptin -15.9 -4.4 
Lipe Lipase, hormone sensitive -11.5 -15.6 
Lmna Lamin A -2.3 -8.9 
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Lpl Lipoprotein lipase -12.1 -3.6 
Lrp5 Low density lipoprotein receptor-related protein 5 -12.7 -1.2 
Mapk13 Mitogen-activated protein kinase 14 -2.5 -8.3 
Ncoa2 Nuclear receptor coactivator 2 -6.9 1.3 
Ncor2 Nuclear receptor co-repressor 2 -40.5 -15.6 
Nr0b2 Nuclear receptor subfamily 0, group B, member 2 -2.9 -15.6 
Nr1h3 Nuclear receptor subfamily 1, group H, member 3 -3.4 -14.4 
Nrf1 Nuclear respiratory factor 1 -2.8 -1.3 
Ppara Peroxisome proliferator activated receptor alpha -7.8 -5.6 
Ppard Peroxisome proliferator activator receptor delta -8.3 -15.6 
Pparg Peroxisome proliferator activated receptor gamma -2.3 -2.1 
Ppargc1a Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha -9.5 -3.7 
Ppargc1b Peroxisome proliferative activated receptor, gamma, coactivator 1 beta -2.5 -1.6 
Prdm16 PR domain containing 16 -68.6 -15.6 
Rb1 Retinoblastoma 1 -5.7 -6.7 
Retn Resistin -27.9 -11.2 
Runx1t1 Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) -68.6 -15.6 
Rxra Retinoid X receptor alpha -8.0 -10.3 
Sfrp1 Secreted frizzled-related protein 1 -68.6 -15.6 
Sfrp5 Secreted frizzled-related sequence protein 5 -48.2 -15.6 
Shh Sonic hedgehog -6.6 -2.9 
Sirt1 
Sirtuin 1 (silent mating type information regulation 2, homolog) 1 (S. 
cerevisiae) -3.5 -15.6 
Sirt2 
Sirtuin 2 (silent mating type information regulation 2, homolog) 2 (S. 
cerevisiae) -18.6 -4.7 
Sirt3 
Sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. 
cerevisiae) -3.8 -3.4 
Slc2a4 Solute carrier family 2 (facilitated glucose transporter), member 4 -4.4 -7.1 
Src Rous sarcoma oncogene -4.6 -15.6 
Srebf1 Sterol regulatory element binding transcription factor 1 -11.5 -44.0 
Taz Tafazzin -6.6 -1.5 
Tcf712 Transcription factor 7-like 2, T-cell specific, HMG-box -1.1 -2.1 
Tsc22d3 TSC22 domain family, member 3 -5.0 -54.9 
Twist1 Twist homolog 1 (Drosophila) -5.0 -15.6 
ucp1 Uncoupling protein 1 (mitochondrial, proton carrier) -27.1 24.4 
Vdr Vitamin D receptor -19.7 -4.9 
Wnt1 Wingless-related MMTV integration site 1 -50.9 -15.6 
Wnt10b Wingless related MMTV integration site 10b -4.4 -8.1 
Wnt3a Wingless-related MMTV integration site 3A -68.6 -5.9 
Wnt5a Wingless-related MMTV integration site 5A -3.9 -1.1 
Wnt5b Wingless-related MMTV integration site 5B -55.7 -2.7 
 
Supplementary Table 2. Expression of 84 adipogenesis-pathway specific genes. Fold 
expression of 84 adipogenesis-specific genes with NPI-110 or NPI-106 peptide-treatment relative 
to BLM-treated group. Negative numbers indicate under-expression and positive numbers indicate 
over-expression of specific gene. Data represents RT-PCR analysis of mRNA from one mouse per 
treatment group with one technical replicate.  
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The transcriptional profiles of NPI-110 and NPI-106 were analyzed using Ingenuity Pathway 
Analysis (IPA) software (Qiagen Bioinformatics, Hilden, Germany). The top twelve IPA-
identified canonical pathways involved in NPI-110 and NPI-106 peptide function included the 
hepatic fibrosis, colorectal cancer metastasis, rheumatoid arthritis, and Tgfb signalling pathways 
(Figure 13A). The top IPA-predicted upstream regulators suggest that the peptides block signalling 
from bleomycin stimulus through the inhibition of Tgfb (Figure 13B).   
Although predicted to be a top IPA-inhibited upstream regulator, Tgfb1 mRNA expression was 
not found to be significantly down-regulated in the profiled fibrosis genes with either peptide 
treatment. This was further investigated with RT-PCR analysis, which confirmed these findings 
(Figure 14). Tgfb1 mRNA expression was not significantly up-regulated in the BLM-treatment 
group, and similarly, showed no significant changes with peptide treatment. Tgfb1 is stored within 
the ECM as a homodimer within a latent complex and requires cleavage of the latency binding 
protein before activation142. These post-translational modifications involved in activation of Tgfb1 
are not reflected in changes in mRNA expression; therefore, immunohistochemical analysis of 
Tgfb1 protein expression was performed to determine if changes were present in Tgfb1 protein 
levels.  
BLM treatment resulted in significantly increased levels of Tgfb1 protein expression in both the 
dermis (p = 0.047) and dermal adipose (p = 0.001) layers. NPI-110 treatment significantly reduced 
Tgfb1 expression by 67% within the dermal adipose layer (p = 0.031) and completely back to 
baseline levels in the dermis (p < 0.0001) (Figure 14). Treatment with NPI-106; however, did not 
decrease Tgfb1 expression in either tissue layer.   
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Figure 13. Focused pathway analysis of top affected canonical pathways and regulators with 
peptide NPI-110 and NPI-106 treatment. (A) Top 12 IPA-predicted affected canonical 
pathways. y-axis shows percent of overlapping up-regulated (green) and down-regulated (red) 
genes in each pathway. Yellow line indicates IPA predicted p-value of overlap. (B) Top 5 IPA-
identified upstream regulators based on ranking of IPA-generated p-values of overlap.  
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Figure 14. Peptide NPI-110 and NPI-106 treatment does not affect Tgfb1 mRNA expression. 
RT-PCR performed on lesional skin from mice after 28 days of either BLM-treatment or BLM-
treatment with peptide injections, with saline injections as control. Values represent mean and 
SEM from three mice per treatment group and five technical replicates. Analysis with one-way 
ANOVA and post-hoc LSD test. (ns, not significant).   
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Figure 15. NPI-110 but not NPI-106 reduces Tgfb1 protein levels within the dermis and 
dermal adipose tissue layers. (A) Paraffin-processed skin sections of mice from all four treatment 
groups at day 28 stained for anti-Tgfb1 antibody. Quantification of immunohistochemical staining 
for Tgfb1 in the dermis (B) and dermal adipose tissue (C). Values represent mean and SEM from 
three random measurements in three sections per mouse, 3 mice per treatment group. Analysis 
with one-way ANOVA and post-hoc LSD test for significance. (* p < 0.05, ** p < 0.001, *** p < 
0.0001).  
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Myc was one of the most significantly down-regulated genes within the profiled fibrosis-specific 
genes with NPI-110 treatment causing 196-fold inhibition in expression (Figure 12). Further 
analysis of the IPA canonical colorectal metastasis pathway show involvement of c-Myc in the 
Wnt/β-catenin, Erk1/2, and Tgfb1 signalling cascades. Pathway analyses predicted that c-Myc, 
one of three members of the Myc family, is downregulated by peptide NPI-110 treatment, and 
predicted to decrease cellular proliferation, growth, and tumor progression (Figure 16). 
Thus, c-Myc was further explored as a potential downstream effector of NPI-110 and NPI-106 
peptide function and its mRNA expression was confirmed with RT-PCR (Figure 17). c-Myc found 
to be increased 2-fold (p = 0.03) with BLM-treatment and was significantly down-regulated with 
both NPI-110 or NPI-106 treatment leading to a 14.4-fold (p < 0.0001) and 111-fold (p < 0.0001) 
decrease compared to baseline, respectively. A similar trend was observed with c-Myc protein 
levels. Immunohistochemical analyses demonstrate a 1.8-fold increase in c-Myc expression with 
BLM-treatment (p = 0.031), and this was significantly reduced by both peptides back to baseline 
(NPI-110 p = 0.013, NPI-106 p = 0.002).  
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Figure 16. Inhibition of c-Myc mRNA expression is predicted within three signalling cascades 
of the canonical metastatic colorectal cancer pathway. Regulatory networks within the IPA 
canonical metastatic colorectal cancer pathway with predicted up-regulated (green) and down-
regulated (red) gene targets.   
 
  
57 
 
 
 
 
 
 
Figure 17. Peptide NPI-110 and NPI-106 treatment decreases c-Myc mRNA expression below 
baseline. RT-PCR performed on lesional skin from mice after 28 days of either BLM-treatment 
or BLM-treatment with peptide injections, with saline injections as control. Values represent mean 
and SEM from three mice per treatment group and five technical replicates. Analysis with one-
way ANOVA and post-hoc LSD test. (* < 0.05, ** < 0.001, *** < 0.0001).   
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Figure 18. Peptide NPI-110 and NPI-106 treatment reduce c-Myc protein expression. (A) 
Paraffin-processed skin sections of mice from all four treatment groups at day 28 stained for anti-
c-Myc antibody. (B) Quantification of immunohistochemical staining for c-Myc. Values represent 
mean and SEM from three random measurements in three sections per mouse, 4 mice per treatment 
group. Analysis with one-way ANOVA and post-hoc LSD test for significance. (* < 0.05, ** p < 
0.001).  
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A key regulator of both these processes, Rhamm mRNA expression was first quantified in BLM-
treated skin. A stress response and signal of tissue damage, Rhamm mRNA expression was 
increased 1.5-fold in the BLM treatment group compared to control (p = 0.03) (Figure 15). NPI-
110 reduced Rhamm expression back to the baseline level of control (p = 0.03) and NPI-106 
treatment resulted in a further 2.8-fold reduction in expression compared to control (p = 0.003) 
(Figure 15). Function-blocking peptides, NPI-110 and NPI-106, block Rhamm signalling at the 
protein level by binding either to Rhamm or LMW-HA. Therefore, the reduction in Rhamm mRNA 
expression is indicative of a regulatory feedback mechanism of Rhamm on its own expression. 
Rhamm signalling may positively feedback to maintain its expression through downstream Erk1 
targeted transcription factors, which is attenuated with peptide treatment.  
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Figure 19. Peptide NPI-110 and NPI-106 attenuate Rhamm mRNA expression. RT-PCR 
performed on lesional skin from mice after 28 days of either BLM-treatment or BLM-treatment 
with peptide injections, with saline injections as control. Values represent mean and SEM from 
three mice per treatment group and five technical replicates. Analysis with one-way ANOVA and 
post-hoc LSD test. (* p < 0.05, ** p < 0.001).   
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5 Discussion 
 
This study investigated the effects of two function-blocking Rhamm peptides, NPI-110 and NPI-
106, in reducing dermal fibrosis and promoting dermal adipogenesis in a mouse model of systemic 
sclerosis. Both peptides were able to reduce dermal thickness; however, only NPI-110 inhibited 
collagen fibrillogenesis as measured by the area fraction of collagen fibrils. Neither peptide 
detectably restored dermal adipose tissue, but NPI-110 treatment increased adipokine expression 
with increased Perilipin mRNA and Adiponectin protein expression. Transcriptomic and pathway 
analyses suggest a mechanism by which Rhamm stabilizes β-catenin, leading to downstream 
activation of pro-fibrosis genes, including Erk1. Erk1 suppresses adipogenesis by inhibiting Pparγ 
and through activating c-Myc, causes clonal proliferation of pre-adipocytes that do not terminally 
differentiate. Erk1 also drives fibrosis through c-Myc induced proliferation of fibroblasts. The 
peptides function by blocking HA-dependent Rhamm signalling and thus suppress β-catenin/Erk1 
driven fibrogenesis and relieve Pparγ suppression, allowing differentiation of mature adipocytes 
(Figure 20).  Thus, Rhamm is hypothesized to acts as a key upstream switch that directs cell fate 
decisions towards fibrosis or adipogenesis.  
 
Collagen and ECM Biomechanics 
In our study, bleomycin treatment induced dermal fibrosis with densely packed collagen fibrils, as 
demonstrated by Masson’s Trichrome and Picrosirius Red staining. Dermal fibrosis can result from 
altered collagen isoform synthesis, processing, or degradation.  Interestingly, in BLM treated skin, 
there was an increase in type 1 collagen mRNA expression, but a decrease in type 3 collagen 
mRNA expression. Normal human skin is comprised of 80% type 1 collagen and 20% type 3 
collagen143, and this Col1a1:Col3a1 ratio is shifted towards more type 1 collagen in stiff scars, 
tissue fibrosis, and systemic sclerosis127,139,144. Type 1 collagen is comprised of two type α1(I) 
chains and one α2 chain in tightly packed fibrils that are cross-linked to form an insoluble matrix 
providing tensile strength and stability145. Type 3 collagen is comprised of three α1(III) chains and 
is randomly dispersed as fine loosely packed fibres that provide pliability to tissues145,146. Peptide 
NPI-110 treatment decreased dermal fibrosis as measured by dermal thickness, area fraction, and 
collagen density.  This effect appears to be primarily due to a decrease in Col1a1 expression and 
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an increase in Col3a1 expression. In contrast, although NPI-106 treatment decreased dermal 
thickness, it did not improve other measures of fibrosis.  Furthermore, although NPI-106 decreased 
Col1a1 expression, it also decreased Col3a1 expression. However, both peptides strongly reduced 
the Col1a1:Col3a1 ratio indicating that type 1 collagen synthesis was more strongly blocked then 
type 3 collagen. A reduction in Col1a1:Col3a1 ratio is commonly used as an indictor of reduced 
tissue fibrosis.  By these criteria, both peptides NPI-110 and NPI-106 are anti-fibrotic, and at least 
one mechanism for this property is blockage of collagen 1 synthesis.    
This conclusion is consistent with previous reports of SSc patient serum and fibroblasts, noting an 
increase in Col1a1:Col3a1 ratio147–149. Given this, there must be a greater increase in the 
accumulation of type 1 collagens within diseased dermis for the ratio of Col1a1:Col3a1 to be 
increased. However, within the present study the temporal relationship between type 1 and 3 
collagen changes are uncertain in that our results represent only one snapshot of mRNA 
expression. For example, the expression of type 3 collagen may have already peaked prior to day 
28, and given the single experimental time-point in these experiments, this trend may have been 
missed.  
Tissue characteristics and pliability are determined not only by collagen type but also the amount 
and type of cross-links. SSc fibroblasts deposit a collagen matrix with dihyroxyl lysine-norleucine 
(DHLNL) cross-links, which are typically only found in collagen of normal cartilage or bone. 
These strongly increase stiffness of the ECM127,150. Fibroblast morphology and behaviour is 
affected by ECM stiffness and the mechanical forces generated through the tissue. Mechanical 
tension placed onto fibroblasts induces the increased production of more ECM products and also 
causes activation of latent Tgfb1 within the ECM151. Mechanical stiffness affects lineage 
commitment in mesenchymal stem cells (MSC) and inhibits adipogenesis. Mouse pre-adipocytes 
embedded in stiffer matrices demonstrate higher concentration of type 1 collagen and reduced 
terminal differentiation into adipocytes152. Similarly, a stiff microenvironment inhibits adipogenic 
differentiation of MSCs by increasing Wnt activation and nuclear β-catenin accumulation153. 
Peptide NPI-110 treatment resulted in increased adiponectin protein and perilipin mRNA 
expression levels compared to BLM treatment alone. Adiponectin is only produced by pre-
adipocytes or adipocytes, and this supports the hypothesis that peptide treatment may create a more 
favourable tissue microenvironment that is conducive to adipogenesis.  
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Differential Effects of NPI-110 and NPI-106 
Two RHAMM function-blocking peptides NPI-110 and NPI-106 were tested for their ability to 
restore normal tissue homeostasis, decrease collagen fibrillogenesis, and promote an adipogenic 
microenvironment. NPI-110 is thought to bind directly to the RHAMM receptor to block its HA-
binding functions.  These function blocking properties reduced dermal thickness and area fraction 
and restored normal skin Col1a1:Col3a1 ratio. NPI-106, which sequesters HA fragments away 
from binding to RHAMM or other HA receptors, reduced dermal thickness and led to decreased 
Col1a1:Col3a1 ratio even below baseline. Neither peptide visually restored dermal adipose tissue 
thickness, although NPI-110 treatment increased adipokine levels. Both peptides strongly blocked 
expression of Rhamm mRNA, and thus affected Rhamm function via different mechanisms.   
The differential effects of the two peptides may be explained by their different mechanisms of 
blocking Rhamm signalling. LMH-HA fragments range from several disaccharides up to 500kDa 
and fragment size affects binding affinity with receptors86,154. Fragmentation of HMW-HA during 
tissue inflammation produces a large variety of fragment sizes. NPI-106 binds to HA, sequestering 
it from Rhamm, but likely binds preferentially to a certain range of LMW-HA fragments. 
Fragments outside of the NPI-106 binding range will still be able to signal through Rhamm, 
leading to incomplete blockade of downstream effects, such as decreased in fibrogenic responses 
and minimal promotion of adipogenesis.  As well, there are other HA receptors such as TLR2,4, 
which are not blocked, that can still bind to HA fragments90,97,155. In contrast, NPI-110, binds 
directly to Rhamm preventing fragments of any size from signalling and likely more specifically 
blocks Rhamm signaling function.   
NPI-110 was modified based on a previous peptide, NPI-102, and acetylated to increase its serum 
half-life. Injections of NPI-110 may produce longer-lasting effects compared to NPI-106, which 
may require more frequently injections to produce the same effects.   
 
RHAMM as a Regulatory Switch Between Fibrosis and Adipogenesis  
Tgfb1 is a key driver of aberrant fibroblast activation and has been implicated in many fibrotic 
diseases30,40,156. Tgfb1 not only promotes resident myofibroblast differentiation and ECM 
production, but is also involved in expanding the population of activated fibroblasts through trans-
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differentiation of other cell types into myofibroblast-like cells35,38,40. Most importantly, Tgfb1 
induces transcriptional reprogramming of adipocytes into activated myofibroblasts39.  
IPA analyses highlighted Tgfb1as one of the top affected canonical pathways and one of the top 
inhibited upstream regulators with peptide treatment (Figure 13). RT-PCR analyses show no 
differences in Tgfb1 mRNA expression among the four treatment groups (Figure 14), which is 
unsurprising since Tgfb1 exists within the extracellular matrix in a bound latent form. Tgfb1 is 
released from this latent complex through conformational changes induced by binding cell-surface 
integrins26. Consistent with the induction of dermal fibrosis, Tgfb1 protein expression was 
increased with BLM-treatment in both the dermis and dermal adipose tissues (Figure 15). This 
effect was ameliorated with NPI-110 treatment, but not with NPI-106.  
Transcriptomic analysis of NPI-110 and NPI-106-treated skin was performed to identify the 
molecular mechanisms involved in Rhamm signalling. All members of the Wnt family assayed in 
the adipogenesis-specific pathway gene panel were potently suppressed with peptide treatment. 
NPI-110 caused a 50.9-fold reduction in Wnt1 and a 4.4-fold reduction in Wnt10b, both of which 
are strongly expressed in fibrotic skin of SSc patients and in multiple other fibrotic diseases157. 
Wnt signalling induces fibroblast activation and release of ECM components. The Wnt proteins 
are secreted ligands that bind to the cell surface receptor Frizzled and induce intracellular 
signalling events leading to the stabilization and nuclear translocation of β-catenin (canonical 
pathway)157. Wnt signalling is tightly regulated by multiple suppressors, including Dickkopf 
(Dkk). Tgfb1 activates the canonical Wnt pathway by inhibiting Dkk, and thus releases Wnt from 
Dkk suppression. Furthermore, inhibition of Wnt signalling ameliorated Tgfb1-induced fibrosis in 
cell culture and animal experiments, demonstrating that Wnt is required for Tgfb1-mediated 
fibrosis62,157. In a seemingly contradictory study, Wei et al found that transgenic mice expressing 
Wnt-10b ectopically in white and brown adipose tissue demonstrated Tgfb1-independent dermal 
fibrosis and subcutaneous lipoatrophy 64. This can be explained by Tgfb1 being upstream of Wnt 
signalling. A transgenic mouse construct that ectopically expresses Wnt would not require Tgfb1 
to relieve Dkk inhibition and therefore, appear to function in a Tgfb1-independent manner. Other 
studies describe the relationship between Tgfb1 and Wnt as reciprocal or interactive with multiple 
levels of cross-talk between downstream components. For example, Axin and β-catenin, both 
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downstream targets of Wnt can regulate the stability of Smad3, a signal transducer of the Tgf1 
pathway158,159.   
β-catenin mediates the effects of Tgfb1 induced fibroblast proliferation in wound repair and is 
especially important in promoting fibroblast motility160–163. β-catenin levels are elevated during 
the proliferative phase of wound healing, and transgenic mice with aberrant β-catenin expression 
in mesenchymal cells developed locally aggressive fibromatoses and exhibit hyperplastic 
wounding responses164. In HT1080 fibrosarcoma cells, immunoprecipitation experiments 
demonstrate formation of intracellular Rhamm, Erk1 and β-catenin complexes, hypothesized to 
protect β-catenin from degradation during nuclear translocation165. In this study, levels of 
cytoplasmic β-catenin were positively regulated by Rhamm and lead to increased proliferation. 
This effect was abrogated with Rhamm knock down and by inhibition of Erk1, which binds directly 
to intracellular Rhamm165. This is further supported by other studies demonstrating a positive 
interaction between HA signalling and Wnt/β-catenin activation. HA treatment of human amniotic 
mesenchymal stem cells increased expression of Wnt1, Wnt3a, Wnt8a, and nuclear localization of 
β-catenin, leading to increased cellular proliferation166. Furthermore, genetic deletion of Rhamm 
in mice showed less aggressive fibromatosis tumour formation, providing further evidence that 
Rhamm is required for β-catenin induced cellular proliferation and motility167.  
β-catenin expression was not directly assayed in our transcriptomic analysis; however, Myc, a 
downstream target of β-catenin168, was down-regulated by both NPI-110 and NPI-106 treatment 
in the fibrosis gene-specific panel. A well-established downstream target of β-catenin, c-Myc is 
one of three members of the Myc family of proto-oncogenes (c-Myc, n-Myc, and l-Myc) involved 
in a broad range of cellular functions including cell-cycle progression, and cellular proliferation 
and differentiation169. c-Myc dysregulation is implicated in more than 50% of human cancers and 
is a ‘super-transcription’ factor regulating transcription of more than 15% of the genome169,170.  
IPA analysis predicted c-Myc to be inhibited within the Wnt/β-catenin, Tgfb1, and Erk1/2 
signalling cascades in the canonical metastatic colorectal cancer pathway (Figure 16). 
Confirmation with RT-PCR demonstrated a 2-fold increase in c-Myc with BLM-treatment, which 
was potently suppressed by both NPI-110 and NPI-106 treatment. Immunohistochemistry also 
confirm these trends at the protein level. HA treatment of quiescent NIH/3T3 cells induced 
accumulation of c-Myc protein stimulated cellular proliferation171, further suggesting that HA and 
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HA receptors, such as Rhamm, are involved in β-catenin signalling of c-Myc. Sears et al. showed 
that the MAP kinases, Erk1,2, phosphorylate c-Myc at serine residue 62 and extends the half-life 
and cellular accumulation of c-Myc172,173.  
Numerous studies indicate that Erk1,2 is downstream of β-catenin and affects cellular proliferation 
and fibroblast contractility26. Erk1,2 complexes with CD44 and Rhamm and is implicated in 
HA/Rhamm-mediated HT1080 fibrosarcoma proliferation165,174 The abnormal cellular 
proliferation in melanoma cells is also related to abnormal Erk1 activity, which was shown to be 
suppressed with β-catenin inhibition. Furthermore, the Tgfb1 activation of human lung fibroblasts 
to myofibroblasts was dependent nuclear β-catenin translocation and Erk1,2 activation175. Lastly,  
Erk1 maintains clonal proliferation of pre-adipocytes105,106, likely through phosphorylation and 
activation of c-Myc. Activation of c-Myc leads to mitotic clonal expansion of 3T3-L1 pre-
adipocytes in culture eventually leading to dysfunctional and small adipocytes176. Sirtuin 1 inhibits 
c-Myc through deacetylation and results in the return of normal functional adipocytes176. 
HA signalling initiated through cell-surface Rhamm leads to the upregulation of intracellular 
Rhamm, through a positive feedback mechanism (Figure 19). BLM treatments led to only a 1.5-
fold increase in Rhamm mRNA expression, which may be explained by the critical role of Rhamm 
as a regulator of cell cycle progression and mitotic spindle orientation and orientation177,178. 
Rhamm overexpression under a strong cytomegalovirus promoter results in cellular apoptosis179. 
Function-blocking Rhamm peptides NPI-110 and NPI-106 blocked Rhamm signalling at the 
protein level but also led to a reduction in Rhamm mRNA expression, pointing towards feedback 
control of Rhamm protein upon its own expression.  
We propose a model where intracellular Rhamm binds to β-catenin and Erk1 forming a complex 
that both stabilizes β-catenin and facilitates its nuclear translocation, leading to downstream 
fibroblast activation and differentiation into myofibroblasts. The Rhamm-β-catenin complex also 
sustains activation of the MAP kinase, Erk. In the nucleus, Erk1 then phosphorylates c-Myc 
leading to the mitotic clonal expansion of pre-adipocytes. Erk1 also inhibits Ppary which prevents 
this expanded pre-adipocyte population from its terminal differentiation into mature adipocytes. 
In this way, HA-dependent Rhamm signalling leads to fibrosis and inhibits adipogenesis (Figure 
20A).  
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Rhamm function-blocking peptides, NPI-110 and NPI-106, inhibit Rhamm signalling and 
downregulates Rhamm expression. This leads to down-regulation of β-catenin, Erk1, and c-Myc 
expression and activity. In this way, the peptides prevent aberrant fibroblast activation and 
differentiation into myofibroblasts and promote the differentiation of pre-adipocytes. Ppary has 
been reported to suppress Tgfb142,156 and Wnt/β-catenin180,181  expression, further decreasing 
fibrotic signalling. Ppary blocks phosphorylation and activation of Erk1, demonstrating 
reciprocally antagonistic regulatory mechanisms between Ppary and Erk1 signaling182. Here, we 
predict that Tgfb1, Wnt/β-catenin, and ERK1 act along the same signalling pathway to control 
fibrosis and adipogenesis, so Ppary may have multiple points of inhibitory action.  The release of 
Erk1 inhibition of Ppary allows terminal differentiation of preadipocytes into mature adipocytes. 
Under the control of Ppary, adipocytes then release adiponectin, a 30 kD adipokine demonstrated 
to have anti-fibrotic effects61,183. mRNA expression of both adiponectin and the adiponectin 
receptors AdipoR1 and AdipoR2 are reduced in primary SSc fibroblasts61. The function-blocking 
Rhamm peptides relieve Ppary suppression from Erk1, leading to increased adiponectin 
production. Together with adiponectin, Ppary suppresses Tgfb1 and Wnt/β-catenin induced 
fibrosis. Thus, Rhamm function-blocking peptides present a potentially novel method of switching 
the rigid fibrotic cellular program towards adipogenesis (Figure 20B).  
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Figure 20. RHAMM acts as a molecular switch between fibrosis and adipogenesis. A) LMW-
HA binds cell-surface Rhamm and upregulates intracellular Rhamm through feedback 
mechanisms, which stabilizes β-catenin. This leads to activation of Erk1 which induces fibrosis 
through c-Myc. Erk1 also inhibits Ppary and prevents a clonally expanded population of pre-
adipocytes from differentiation into mature adipocytes. B) Function-blocking Rhamm peptides 
bind to either LMW-HA or to cell-surface Rhamm which downregulates intracellular Rhamm. 
This reduces fibrosis by preventing activation of Erk1 and c-Myc. Ppary is no longer inhibited by 
Erk1 and is able to induce terminal differentiation of pre-adipocytes, leading to an increase in 
adipogenesis.  
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Regeneration of Adipocytes 
In SSc, the trans-differentiation of adipocytes into fibroblasts contributes to the loss of dermal 
adipose tissue41. This phenotypic plasticity between adipocytes and fibroblasts can be targeted as 
a method for reversing fibrosis. Maksin et al. demonstrated that adipocytes also regenerate from 
myofibroblasts during wound healing in mice, and that human keloid fibroblasts can trans-
differentiate into adipocytes184. Both transformations are dependent on bone morphogenic protein 
(Bmp) signalling.  
Bmp is a growth factor and member of the Tgfb superfamily that directs adipogenic 
commitment185,186. The Wnt1 inducible signaling pathway protein 2 (WISP2) binds to and inhibits 
zinc finger protein 423 (Zfp423), which is a transcriptional activator of Ppary. This prevents Ppary 
activation. BMP4 dissociates the WISP2-Zfp423 complex, allowing Zfp423 to translocate into the 
nucleus and activate PPARy185. Zfp423 is critical to myofibroblast-adipocyte trans-differentiation, 
as Zfp423 mutant mice are unable to regenerate adipocytes184. Rhamm function-blocking peptides 
decrease Wnt signalling and thus may either facilitate, or contribute directly to, myofibroblast 
reversion to adipocytes. Reverting myofibroblasts into adipocytes is a potential method to directly 
reverse the underlying pathophysiology of SSc and an exciting potential novel therapeutic option 
in SSc treatment.  Future experiments to delineate the interaction between Bmp and Rhamm will 
help to elucidate this connection. 
 
Peptide Adjuncts to Autologous Lipotransfer 
In addition to directly ameliorating fibrosis by targeting fibroblast activation, the Rhamm function-
blocking peptides increased adipokine expression and are hypothesized to create a pro-adipogenic 
environment, which not only contributes to dampening fibrosis but also presents a useful adjunct 
for enhancing the efficacy of autologous lipotransfer therapies. Autologous lipotransfer has 
recently emerged as a potential treatment option for cutaneous fibrosis187–190. Elective lipotransfer 
is  safe, well-tolerated, and a commonly performed procedure in plastic surgery with minimal 
complications189,191,192. Lipotransfer therapy directly addresses the loss of dermal adipose tissue, 
helps with soft tissue filling, and increases the pliability of the skin. However, the unpredictable 
patient to patient variability in graft retention remains an important clinical problem.   
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The lipoaspirate contains adipose-derived stem cell (ADSC) populations, which have intrinsic 
regenerative and anti-fibrotic properties. ADSCs retain developmental plasticity and can undergo 
self-renewal193. Lipotransfer studies in animal models of fibrosis show decreased dermal thickness 
and Tgfb1 suppression with ADSC injections194–196. Early experience with the treatment of SSc 
patients with oro-facial fibrosis demonstrated restoration of facial lipoatrophy, increased oral 
perimeter, improved mouth opening, and decreased pain scores187,197. Similar results were seen in 
twelve SSc patients undergoing ADSC injections to the hands198. The effects of a one-time 
treatment improved hand functioning, hand pain, and decreased the incidence of digital ulcers, 
which was sustained at one-year follow-up198.  
Inherent difficulties with lipotransfer procedures include predicting the amount of fat retention and 
issues with fat necrosis, as not all transferred fat survive in the grafted areas. This remains a key 
limitation requiring further investigation and optimization. Function-blocking Rhamm peptides 
should be further explored as a potential adjunct to lipotransfer therapy to improve fat retention.  
 
Clinical Translation  
 
Function-blocking Rhamm peptides present a potentially novel method of reversing cutaneous 
fibrosis in systemic sclerosis. Recent studies have highlighted the dynamic and reversible nature 
of fibrosis in the liver, heart, kidney and lungs, with the potential for almost complete restitution 
of normal tissue architecture199–201. In animal models of liver and lung fibrosis, the cessation of 
fibrogenic cytokine signalling leads to the depletion of macrophages, myofibroblast senescence 
and apoptosis, and degradation of the extracellular matrix201,202. This is further supported in human 
diseases with liver biopsy histology specimens showing resolution of fibrosis in patients 
successfully treated for hepatitis C infection199. Cutaneous fibrosis, in animal models of BLM 
induced fibrosis, was fully reversed 6 weeks after the cessation of subcutaneous injections203. 
Thus, a longer duration of peptide treatment may demonstrate even further reduction of fibrosis. 
The future development of peptides amenable to topical application would preclude the discomfort 
of repeated subcutaneous injections.  
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Limitations and Future Directions 
Limitations of this study include the technical aspects of standardizing BLM injections. BLM was 
injected subcutaneously into the dorsal back skin of mice. This area was shaved prior to injections 
but the location of injection was estimated within this area and not precisely standardized. The 
BLM-induced SSc mouse model exhibits localized cutaneous fibrosis around the area of injection 
but not at distant sites123. The effect size of BLM injection sites is unknown and there may be a 
gradient effect proportional to distance away from injection site. Skin biopsies were taken in the 
same region of injections but standardized exactly over the injection point. Future experiments 
should include tattooing four points to delineate a 1cm x 1cm square region marking the injection 
and skin biopsy site to ensure accurate and standardized tissue sampling. Tattooing directly over 
the point of injection could lead to aberrant pigment and potential inflammatory effects. 
Furthermore, instead of normal saline injections in the control group, a better control would be the 
use of a control peptide in which the key amino acids required for binding to Rhamm (NPI-110) 
or HA (NPI-106) are mutated leading to a non-functional peptide. Logistical limitations also 
precluded the testing of multiple peptide concentrations and dosing regimens. Both require further 
optimization within the BLM-induced SSc mouse model. 
In our study, peptide treatments did not lead to a measurable difference in dermal adipose tissue 
but did increase adiponectin protein and perilipin mRNA expression. Measurement of dermal 
adipose tissue thickness using histology sections is an imprecise measure of adipogenesis. Small 
detected differences on a two-dimensional slide may be representative of larger overall volumetric 
changes. Three-dimensional volumetric analysis of adipose tissue with high frequency ultrasound 
and whole animal micro-CT have been described and represent more accurate methods of 
quantifying changes in adipose tissue107,122. Future experiments including measurement of serum 
adiponectin and collagen tripeptides will further characterize the systemic effect of peptide 
injections. Mice were sacrificed on day 28 and a longer observational and treatment period may 
also have been required to detect the restoration of dermal adipose architecture.  
A further limitation is the examination of lesional skin at only one time-point, on day 28. 
Examination of fibrosis and adipogenic markers at earlier and later time-points may help to 
elucidate the effects of peptide treatment on early inflammatory markers and to evaluate ongoing 
adipogenic changes. This would also provide more information on whether type 3 collagen peaks 
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earlier in the development of BLM-induced fibrosis compared to type 1 collagen. Our study 
demonstrated a decrease in type 3 collagen by day 28 which may represent a true reduction or the 
downward trend after an earlier peak in expression. Future experiments with peptide injections for 
a longer duration would provide more information on whether Rhamm peptide injection leads to 
the eventual return of dermal adipose architecture and fully reverses dermal thickening. Peptide 
treatments resulted in a 6% decrease in dermal thickness and this effect may show further 
improvement with prolonged treatments. Experiments including additional controls of peptide 
only injection in the absence of BLM will help to determine the effect of peptide injection in 
healthy tissue and to ensure that the observed effects are specific. Future studies will include 
pathway analysis to confirm the involvement of β-catenin, Erk1, and c-Myc through Western blot 
and co-immunoprecipitation experiments. First, β-catenin RT-PCR and immunohistochemical 
analysis will confirm whether β-catenin is overexpressed and drives BLM-induced SSc. β-catenin 
mRNA and protein expression should be reduced with peptide treatment. Next co-
immunoprecipitation experiments will identify the β-catenin-Rhamm complex, which should be 
dissociated with the application of Rhamm function-blocking peptides. To determine if the 
peptides function through the regulation of β-catenin, both gain of function and loss of function β-
catenin mouse models will be tested. Constitutively activated β-catenin activity can be induced 
using a Cre-lox mouse with fibroblast specific deletion of exon 3 of β-catenin204, which contains 
its degradation site. In this mouse, constitutively active β-catenin should induce dermal fibrosis 
and loss of dermal adipose tissue regardless of Rhamm peptide treatment. Conversely, fibroblast 
specific deletion of β-catenin using the Ctnnb1fl/fl mouse (deletion of introns 1 and 6 of β-catenin 
gene)204 should be resistant to BLM-induced SSc and dermal fibrosis. In both of these models, 
mRNA and protein expression of c-Myc, Erk1, and Ppary will be assayed. Together, these 
experiments will elucidate the mechanism by which Rhamm controls fibrosis and adipogenesis 
and provide a more thorough understanding of peptide function.   
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6 Conclusions 
 
In a mouse model of BLM-induced systemic sclerosis, Rhamm function-blocking peptides reduce 
dermal fibrosis and increase adipokine expression. Transcriptomic analyses suggest a pathway 
where Rhamm function-blocking peptides lead to the down-regulation of β-catenin, Erk1, and c-
Myc signalling, which decreases fibroblast activation and promotes terminal adipocyte 
differentiation. These results support future applications of Rhamm peptides as a primary 
therapeutic agent for the treatment of cutaneous fibrosis in systemic sclerosis.  
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